{
  "document_id": "5326ab75",
  "zip_file": "ffgg0257.zip",
  "category": "Presentations",
  "content_file": {
    "file_name": "ffgg0257.pdf",
    "file_path": "Presentations/ffgg0257.zip/ffgg0257.pdf",
    "extracted_text": "=== Page 1 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nHigh level assessment of potential strategic options for Oxycontin\n1 Only include Commercial and Part D accounts\n2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza losing 60-70%% of the market share due to exclusion\n2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza share grow by 10-40% YoY\n3 Assuming  Oxycontin share drops by 65%  in 2020  and by 30% YoY in 2021 and 2022 due to exclusion, and Xtampza captures 75% of the share drop from Oxycontin\nKey assumptions, 2022\n3 year financial projection of net sales1 (after rebates and other GtN \nreductions)\nMaintaining current access status could offer highest cumulative net \nsales in the longer term \n13\n%2 \n2%4\n10\n%3\nOxycontin \nShare\nOxycontin \nrebate\nCommercial: \n50%\nMedicare: \n70%\n0%\nCommercial: \n45%\nMedicare: \n69%\n(assuming \n2% increase \nYoY)\nOxycontin net sales1 ($M) \nXtampza net sales1 ($M)\n273\n227\n202\n702\nSecure \nexclusive \nposition \nacross all \ncontracted \naccounts \nMaintain \ncurrent \naccess \nstatus with \nincreasing \nrebates\nPull away \nrebates \nfrom all \naccounts\nxx\n3 year \ntotal\n297\n240\n206\n270\n179\n128\n2020\n21\n2022\n743\n577\n146\n199\n348\n44\n55\n47\n66\n65\n69\n120\n115\n113\n21\n2020\n2022\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 1 Image 1 (OCR) ===\n—\n\n=== Page 1 Image 2 (OCR) ===\noe\n\n=== Page 1 Image 3 (OCR) ===\na\n\n=== Page 1 Image 4 (OCR) ===\nQunoue).\n\n=== Page 1 Image 6 (OCR) ===\nguaoue)\n\n=== Page 1 Image 7 (OCR) ===\na\n\n=== Page 1 Image 8 (OCR) ===\nuaoue).\n\n=== Page 1 Image 9 (OCR) ===\neuaoue).\n\n=== Page 1 Image 10 (OCR) ===\na\n\n=== Page 1 Image 11 (OCR) ===\n—\n\n=== Page 1 Image 12 (OCR) ===\noe\n\n=== Page 1 Image 13 (OCR) ===\na\n\n=== Page 1 Image 14 (OCR) ===\nQunoue).\n\n=== Page 1 Image 16 (OCR) ===\nguaoue)\n\n=== Page 1 Image 17 (OCR) ===\na\n\n=== Page 1 Image 18 (OCR) ===\nuaoue).\n\n=== Page 1 Image 19 (OCR) ===\neuaoue).\n\n=== Page 1 Image 20 (OCR) ===\na\n\n=== Page 1 Image 21 (OCR) ===\n—\n\n=== Page 1 Image 22 (OCR) ===\noe\n\n=== Page 1 Image 23 (OCR) ===\na\n\n=== Page 1 Image 24 (OCR) ===\nQunoue).\n\n=== Page 1 Image 26 (OCR) ===\nguaoue)\n\n=== Page 1 Image 27 (OCR) ===\na\n\n=== Page 1 Image 28 (OCR) ===\nuaoue).\n\n=== Page 1 Image 29 (OCR) ===\neuaoue).\n\n=== Page 1 Image 30 (OCR) ===\na\n\n=== Page 1 Image 31 (OCR) ===\n—\n\n=== Page 1 Image 32 (OCR) ===\noe\n\n=== Page 1 Image 33 (OCR) ===\na\n\n=== Page 1 Image 34 (OCR) ===\nQunoue).\n\n=== Page 1 Image 36 (OCR) ===\nguaoue)\n\n=== Page 1 Image 37 (OCR) ===\na\n\n=== Page 1 Image 38 (OCR) ===\nuaoue).\n\n=== Page 1 Image 39 (OCR) ===\neuaoue).\n\n=== Page 1 Image 40 (OCR) ===\na\n\n=== Page 1 Image 41 (OCR) ===\n—\n\n=== Page 1 Image 42 (OCR) ===\noe\n\n=== Page 1 Image 43 (OCR) ===\na\n\n=== Page 1 Image 44 (OCR) ===\nQunoue).\n\n=== Page 1 Image 46 (OCR) ===\nguaoue)\n\n=== Page 1 Image 47 (OCR) ===\na\n\n=== Page 1 Image 48 (OCR) ===\nuaoue).\n\n=== Page 1 Image 49 (OCR) ===\neuaoue).\n\n=== Page 1 Image 50 (OCR) ===\na\n\n=== Page 1 Image 51 (OCR) ===\n—\n\n=== Page 1 Image 52 (OCR) ===\noe\n\n=== Page 1 Image 53 (OCR) ===\na\n\n=== Page 1 Image 54 (OCR) ===\nQunoue).\n\n=== Page 1 Image 56 (OCR) ===\nguaoue)\n\n=== Page 1 Image 57 (OCR) ===\na\n\n=== Page 1 Image 58 (OCR) ===\nuaoue).\n\n=== Page 1 Image 59 (OCR) ===\neuaoue).\n\n=== Page 1 Image 60 (OCR) ===\na\n\n=== Page 1 Image 61 (OCR) ===\n—\n\n=== Page 1 Image 62 (OCR) ===\noe\n\n=== Page 1 Image 63 (OCR) ===\na\n\n=== Page 1 Image 64 (OCR) ===\nQunoue).\n\n=== Page 1 Image 66 (OCR) ===\nguaoue)\n\n=== Page 1 Image 67 (OCR) ===\na\n\n=== Page 1 Image 68 (OCR) ===\nuaoue).\n\n=== Page 1 Image 69 (OCR) ===\neuaoue).\n\n=== Page 1 Image 70 (OCR) ===\na\n\n=== Page 2 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n• OxyContin and Hysingla ER maintain strong access on Envision’s formularies, with OxyContin maintaining preferred status on 66% of \nlives \n• Collegium’s products are nearly completely excluded on all Envision formularies\n1 Defined as percentage of lives that are either preferred or covered (including PA/ST)\nCurrent access status: OxyContin is preferred for 66% of lives on Envision Part D formularies\n2\nSOURCE: MMIT\n25\n466\n203\n27\n51\nNot \nCovered\nPreferre\nd\nCovered \n(PA/ST)\nNot \nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST)\nPreferre\nd\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nPrivileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal \nand regulatory review before they can be considered final. These materials are confidential and proprietary.\nMCS Classicare II\nHealthSun MediMax \nPreferre\nd\nNot \nCovered\nPreferre\nd\nNot \nCovered\nEnvisionRxPlus PDP\nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST)\n74%\n1%\n92%\n0%\n65%\nEnvisionRxPlus Hybrid PDP\nHealthTeam Advantage Plan\nCovered \n(PA/ST)\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nLives, K\nOverall formulary \nstatus\nLives, \n%\nHysingl\na ER\nXtampz\na ER\nOxyCo\nntin\nNucynt\na ER\nZohydr\no ER\nLargest formulary\nPurdue \npreferred, \nZohydro covered\nOnly Oxycontin \ncovered\nPurdue portfolio \nexclusive \ncoverage \nOnly branded \nhydrocodone \ncoverage\nOnly Hysingla ER \ncovered\nOverall covered \nlives %1\n59\n%\n26\n%\n7%\n3%\n3%\nOxycontin Covered\nNot covered\nCoverage status of leading ERO brands, \nNov 2018\nENVISION\n789\nTotal\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 2 Image 1 (OCR) ===\n—\n\n=== Page 2 Image 2 (OCR) ===\noe\n\n=== Page 2 Image 3 (OCR) ===\na\n\n=== Page 2 Image 4 (OCR) ===\nQunoue).\n\n=== Page 2 Image 6 (OCR) ===\nguaoue)\n\n=== Page 2 Image 7 (OCR) ===\na\n\n=== Page 2 Image 8 (OCR) ===\nuaoue).\n\n=== Page 2 Image 9 (OCR) ===\neuaoue).\n\n=== Page 2 Image 10 (OCR) ===\na\n\n=== Page 2 Image 11 (OCR) ===\n—\n\n=== Page 2 Image 12 (OCR) ===\noe\n\n=== Page 2 Image 13 (OCR) ===\na\n\n=== Page 2 Image 14 (OCR) ===\nQunoue).\n\n=== Page 2 Image 16 (OCR) ===\nguaoue)\n\n=== Page 2 Image 17 (OCR) ===\na\n\n=== Page 2 Image 18 (OCR) ===\nuaoue).\n\n=== Page 2 Image 19 (OCR) ===\neuaoue).\n\n=== Page 2 Image 20 (OCR) ===\na\n\n=== Page 2 Image 21 (OCR) ===\n—\n\n=== Page 2 Image 22 (OCR) ===\noe\n\n=== Page 2 Image 23 (OCR) ===\na\n\n=== Page 2 Image 24 (OCR) ===\nQunoue).\n\n=== Page 2 Image 26 (OCR) ===\nguaoue)\n\n=== Page 2 Image 27 (OCR) ===\na\n\n=== Page 2 Image 28 (OCR) ===\nuaoue).\n\n=== Page 2 Image 29 (OCR) ===\neuaoue).\n\n=== Page 2 Image 30 (OCR) ===\na\n\n=== Page 2 Image 31 (OCR) ===\n—\n\n=== Page 2 Image 32 (OCR) ===\noe\n\n=== Page 2 Image 33 (OCR) ===\na\n\n=== Page 2 Image 34 (OCR) ===\nQunoue).\n\n=== Page 2 Image 36 (OCR) ===\nguaoue)\n\n=== Page 2 Image 37 (OCR) ===\na\n\n=== Page 2 Image 38 (OCR) ===\nuaoue).\n\n=== Page 2 Image 39 (OCR) ===\neuaoue).\n\n=== Page 2 Image 40 (OCR) ===\na\n\n=== Page 2 Image 41 (OCR) ===\n—\n\n=== Page 2 Image 42 (OCR) ===\noe\n\n=== Page 2 Image 43 (OCR) ===\na\n\n=== Page 2 Image 44 (OCR) ===\nQunoue).\n\n=== Page 2 Image 46 (OCR) ===\nguaoue)\n\n=== Page 2 Image 47 (OCR) ===\na\n\n=== Page 2 Image 48 (OCR) ===\nuaoue).\n\n=== Page 2 Image 49 (OCR) ===\neuaoue).\n\n=== Page 2 Image 50 (OCR) ===\na\n\n=== Page 2 Image 51 (OCR) ===\n—\n\n=== Page 2 Image 52 (OCR) ===\noe\n\n=== Page 2 Image 53 (OCR) ===\na\n\n=== Page 2 Image 54 (OCR) ===\nQunoue).\n\n=== Page 2 Image 56 (OCR) ===\nguaoue)\n\n=== Page 2 Image 57 (OCR) ===\na\n\n=== Page 2 Image 58 (OCR) ===\nuaoue).\n\n=== Page 2 Image 59 (OCR) ===\neuaoue).\n\n=== Page 2 Image 60 (OCR) ===\na\n\n=== Page 2 Image 61 (OCR) ===\n—\n\n=== Page 2 Image 62 (OCR) ===\noe\n\n=== Page 2 Image 63 (OCR) ===\na\n\n=== Page 2 Image 64 (OCR) ===\nQunoue).\n\n=== Page 2 Image 66 (OCR) ===\nguaoue)\n\n=== Page 2 Image 67 (OCR) ===\na\n\n=== Page 2 Image 68 (OCR) ===\nuaoue).\n\n=== Page 2 Image 69 (OCR) ===\neuaoue).\n\n=== Page 2 Image 70 (OCR) ===\na\n\n=== Page 3 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe defined potential 2020 access scenarios for Oxycontin vs. Xtampza\n2020 Share shift assumptions under different scenarios, 2020 Q4 \n2020 access \nscenarios\nContinue current \naccess status as  \nexclusive preferred \noxycodone ER\n1\nBoth Oxycontin and \nXtampza preferred \n2\nXtampza preferred, \nOxycontin non-\npreferred\n3\nXtampza replaces \nOxycontin as \nexclusive preferred \nwith \ngrandfathering\n4\nOxycontin Excluded \nwithout \ngrandfathering\n5\n5\n1\n22\n6\n15\n8\n7\n8\n3\n12\n9\n5\n4\n11\n22\n8\n9\n22\n6\n8\n6\n9\n8\n9\n7\n6\n9\n3\n10\n22\n22\n22\n22\n22\n22\n7\nOxycontin\nXtampza\nOther brands\nShare by products (exit share) \nShare shift vs. \nstatus quo \nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\n20%\n40%\n30%\n68%\n50%\n70%\n60%\n80%\n0%\nPRIME\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 3 Image 1 (OCR) ===\n—\n\n=== Page 3 Image 2 (OCR) ===\noe\n\n=== Page 3 Image 3 (OCR) ===\na\n\n=== Page 3 Image 4 (OCR) ===\nQunoue).\n\n=== Page 3 Image 6 (OCR) ===\nguaoue)\n\n=== Page 3 Image 7 (OCR) ===\na\n\n=== Page 3 Image 8 (OCR) ===\nuaoue).\n\n=== Page 3 Image 9 (OCR) ===\neuaoue).\n\n=== Page 3 Image 10 (OCR) ===\na\n\n=== Page 3 Image 11 (OCR) ===\n—\n\n=== Page 3 Image 12 (OCR) ===\noe\n\n=== Page 3 Image 13 (OCR) ===\na\n\n=== Page 3 Image 14 (OCR) ===\nQunoue).\n\n=== Page 3 Image 16 (OCR) ===\nguaoue)\n\n=== Page 3 Image 17 (OCR) ===\na\n\n=== Page 3 Image 18 (OCR) ===\nuaoue).\n\n=== Page 3 Image 19 (OCR) ===\neuaoue).\n\n=== Page 3 Image 20 (OCR) ===\na\n\n=== Page 3 Image 21 (OCR) ===\n—\n\n=== Page 3 Image 22 (OCR) ===\noe\n\n=== Page 3 Image 23 (OCR) ===\na\n\n=== Page 3 Image 24 (OCR) ===\nQunoue).\n\n=== Page 3 Image 26 (OCR) ===\nguaoue)\n\n=== Page 3 Image 27 (OCR) ===\na\n\n=== Page 3 Image 28 (OCR) ===\nuaoue).\n\n=== Page 3 Image 29 (OCR) ===\neuaoue).\n\n=== Page 3 Image 30 (OCR) ===\na\n\n=== Page 3 Image 31 (OCR) ===\n—\n\n=== Page 3 Image 32 (OCR) ===\noe\n\n=== Page 3 Image 33 (OCR) ===\na\n\n=== Page 3 Image 34 (OCR) ===\nQunoue).\n\n=== Page 3 Image 36 (OCR) ===\nguaoue)\n\n=== Page 3 Image 37 (OCR) ===\na\n\n=== Page 3 Image 38 (OCR) ===\nuaoue).\n\n=== Page 3 Image 39 (OCR) ===\neuaoue).\n\n=== Page 3 Image 40 (OCR) ===\na\n\n=== Page 3 Image 41 (OCR) ===\n—\n\n=== Page 3 Image 42 (OCR) ===\noe\n\n=== Page 3 Image 43 (OCR) ===\na\n\n=== Page 3 Image 44 (OCR) ===\nQunoue).\n\n=== Page 3 Image 46 (OCR) ===\nguaoue)\n\n=== Page 3 Image 47 (OCR) ===\na\n\n=== Page 3 Image 48 (OCR) ===\nuaoue).\n\n=== Page 3 Image 49 (OCR) ===\neuaoue).\n\n=== Page 3 Image 50 (OCR) ===\na\n\n=== Page 3 Image 51 (OCR) ===\n—\n\n=== Page 3 Image 52 (OCR) ===\noe\n\n=== Page 3 Image 53 (OCR) ===\na\n\n=== Page 3 Image 54 (OCR) ===\nQunoue).\n\n=== Page 3 Image 56 (OCR) ===\nguaoue)\n\n=== Page 3 Image 57 (OCR) ===\na\n\n=== Page 3 Image 58 (OCR) ===\nuaoue).\n\n=== Page 3 Image 59 (OCR) ===\neuaoue).\n\n=== Page 3 Image 60 (OCR) ===\na\n\n=== Page 3 Image 61 (OCR) ===\n—\n\n=== Page 3 Image 62 (OCR) ===\noe\n\n=== Page 3 Image 63 (OCR) ===\na\n\n=== Page 3 Image 64 (OCR) ===\nQunoue).\n\n=== Page 3 Image 66 (OCR) ===\nguaoue)\n\n=== Page 3 Image 67 (OCR) ===\na\n\n=== Page 3 Image 68 (OCR) ===\nuaoue).\n\n=== Page 3 Image 69 (OCR) ===\neuaoue).\n\n=== Page 3 Image 70 (OCR) ===\na\n\n=== Page 4 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n10.8\n11.0\n11.5\n13.2\n7.2\n6.2\n11.2\n7.9\n10.2\n6.6\n2020 access \nscenarios\nBoth \nOxycontin and \nXtampza \npreferred \nXtampza \npreferred, \nOxycontin \nnon-preferred\nContinue \ncurrent access \nstatus as  \nexclusive \npreferred\noxycodone ER\nXtampza \nreplacing \nOxycontin as \nexclusive \npreferred with \ngrandfathering\nOxycontin \nExcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n4\n0%\n40%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\ns to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. \n2.1\n3.2\n0.8\n2.9\n1.6\n1.1\n1.8\n1.6\nShare by \nproduct, 2020 \nQ4\nOther brand \nnet sales ($M)\n5\n3\n22\n9\n8\n7\n12\n22\n6\n4\n5\n9\n6\n8\n11\n9\n7\n6\n8\n22\n8\n5\n9\n8\n9\n7\n10\n3\n22\n22\n22\n22\n22\n8.0\n7.3\n7.7\n8.8\n8.4\n8.8\n9.2\n9.6\nOxycontin\nOther brands\nXtampza\nPRIME\n0.7\n22\n6\n1\n15\n6.5\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nShar\ne \nshift\nBreak-\neven \nrebate2 \n37%\n48%\n32%\n37%\nN/A\n30%\n44%\n60%\n45%\nNet sales at min \nrebate ($M)\n42%\nRebate rate to keep \nPrime whole1 \n30%\n44%\n27%\n40%\nN/A\n24%\n36%\n32%\nTheoretic\nal – \nunlikely \nable to \nlower \ncurrent \nrate \n(40%)\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 4 Image 1 (OCR) ===\n—\n\n=== Page 4 Image 2 (OCR) ===\noe\n\n=== Page 4 Image 3 (OCR) ===\na\n\n=== Page 4 Image 4 (OCR) ===\nQunoue).\n\n=== Page 4 Image 6 (OCR) ===\nguaoue)\n\n=== Page 4 Image 7 (OCR) ===\na\n\n=== Page 4 Image 8 (OCR) ===\nuaoue).\n\n=== Page 4 Image 9 (OCR) ===\neuaoue).\n\n=== Page 4 Image 10 (OCR) ===\na\n\n=== Page 4 Image 11 (OCR) ===\n—\n\n=== Page 4 Image 12 (OCR) ===\noe\n\n=== Page 4 Image 13 (OCR) ===\na\n\n=== Page 4 Image 14 (OCR) ===\nQunoue).\n\n=== Page 4 Image 16 (OCR) ===\nguaoue)\n\n=== Page 4 Image 17 (OCR) ===\na\n\n=== Page 4 Image 18 (OCR) ===\nuaoue).\n\n=== Page 4 Image 19 (OCR) ===\neuaoue).\n\n=== Page 4 Image 20 (OCR) ===\na\n\n=== Page 4 Image 21 (OCR) ===\n—\n\n=== Page 4 Image 22 (OCR) ===\noe\n\n=== Page 4 Image 23 (OCR) ===\na\n\n=== Page 4 Image 24 (OCR) ===\nQunoue).\n\n=== Page 4 Image 26 (OCR) ===\nguaoue)\n\n=== Page 4 Image 27 (OCR) ===\na\n\n=== Page 4 Image 28 (OCR) ===\nuaoue).\n\n=== Page 4 Image 29 (OCR) ===\neuaoue).\n\n=== Page 4 Image 30 (OCR) ===\na\n\n=== Page 4 Image 31 (OCR) ===\n—\n\n=== Page 4 Image 32 (OCR) ===\noe\n\n=== Page 4 Image 33 (OCR) ===\na\n\n=== Page 4 Image 34 (OCR) ===\nQunoue).\n\n=== Page 4 Image 36 (OCR) ===\nguaoue)\n\n=== Page 4 Image 37 (OCR) ===\na\n\n=== Page 4 Image 38 (OCR) ===\nuaoue).\n\n=== Page 4 Image 39 (OCR) ===\neuaoue).\n\n=== Page 4 Image 40 (OCR) ===\na\n\n=== Page 4 Image 41 (OCR) ===\n—\n\n=== Page 4 Image 42 (OCR) ===\noe\n\n=== Page 4 Image 43 (OCR) ===\na\n\n=== Page 4 Image 44 (OCR) ===\nQunoue).\n\n=== Page 4 Image 46 (OCR) ===\nguaoue)\n\n=== Page 4 Image 47 (OCR) ===\na\n\n=== Page 4 Image 48 (OCR) ===\nuaoue).\n\n=== Page 4 Image 49 (OCR) ===\neuaoue).\n\n=== Page 4 Image 50 (OCR) ===\na\n\n=== Page 4 Image 51 (OCR) ===\n—\n\n=== Page 4 Image 52 (OCR) ===\noe\n\n=== Page 4 Image 53 (OCR) ===\na\n\n=== Page 4 Image 54 (OCR) ===\nQunoue).\n\n=== Page 4 Image 56 (OCR) ===\nguaoue)\n\n=== Page 4 Image 57 (OCR) ===\na\n\n=== Page 4 Image 58 (OCR) ===\nuaoue).\n\n=== Page 4 Image 59 (OCR) ===\neuaoue).\n\n=== Page 4 Image 60 (OCR) ===\na\n\n=== Page 4 Image 61 (OCR) ===\n—\n\n=== Page 4 Image 62 (OCR) ===\noe\n\n=== Page 4 Image 63 (OCR) ===\na\n\n=== Page 4 Image 64 (OCR) ===\nQunoue).\n\n=== Page 4 Image 66 (OCR) ===\nguaoue)\n\n=== Page 4 Image 67 (OCR) ===\na\n\n=== Page 4 Image 68 (OCR) ===\nuaoue).\n\n=== Page 4 Image 69 (OCR) ===\neuaoue).\n\n=== Page 4 Image 70 (OCR) ===\na\n\n=== Page 5 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nLong term view: 2020-2022 financial impact under different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n20.3\n17.3\n10.2\n14.5\n16.0\n19.4\n12.5\n19.2\nAccess scenarios\nBoth Oxycontin \nand Xtampza \npreferred \nXtampza \npreferred, \nOxycontin non-\npreferred\nContinue current \naccess status as  \nexclusive preferred\noxycodone ER\nXtampza replacing \nOxycontin as \nexclusive preferred \nwith grandfathering\n60%\n50%\n43%\n5%\n0%\nOxycontin \nExcluded without \ngrandfathering\n2020\n1\n2\n3\n4\nAssumed \nOxycontin \nrebate, 2022\n3 year total ($M)\nShare \nshift\nMaintaining  current access status could maximize net sales in the longer term as well, assuming reasonable increase in rebate rate\n6.6\n10.6\n9.6\n8.7\n10.2\n7.5\n10.6\n11.1\nShare by \nproduct, 2022 \nQ4\n2021\n5\n20\n3\n5\n20\n4\n8\n20\n9\n7\n10\n7\n8\n8\n5\n9\n7\n9\n9\n9\n2\n9\n20\n10\n20\n1\n20\n9\n1\n9\n1\n20\n20\n3.4\n6.0\n2.6\n5.6\n6.4\n4.8\n3.4\n5.1\nOxycontin\nOther brands\nXtampza\nPRIME\n10.8\n0 6\n13\n20\n7.3\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nOxycontin net sales ($M)\n2022\n4.3\n2.8\n3.3\n1.5\n2.5\n1.6\n2.4\n1.0\n2.0\n22.4\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 5 Image 1 (OCR) ===\n—\n\n=== Page 5 Image 2 (OCR) ===\noe\n\n=== Page 5 Image 3 (OCR) ===\na\n\n=== Page 5 Image 4 (OCR) ===\nQunoue).\n\n=== Page 5 Image 6 (OCR) ===\nguaoue)\n\n=== Page 5 Image 7 (OCR) ===\na\n\n=== Page 5 Image 8 (OCR) ===\nuaoue).\n\n=== Page 5 Image 9 (OCR) ===\neuaoue).\n\n=== Page 5 Image 10 (OCR) ===\na\n\n=== Page 5 Image 11 (OCR) ===\n—\n\n=== Page 5 Image 12 (OCR) ===\noe\n\n=== Page 5 Image 13 (OCR) ===\na\n\n=== Page 5 Image 14 (OCR) ===\nQunoue).\n\n=== Page 5 Image 16 (OCR) ===\nguaoue)\n\n=== Page 5 Image 17 (OCR) ===\na\n\n=== Page 5 Image 18 (OCR) ===\nuaoue).\n\n=== Page 5 Image 19 (OCR) ===\neuaoue).\n\n=== Page 5 Image 20 (OCR) ===\na\n\n=== Page 5 Image 21 (OCR) ===\n—\n\n=== Page 5 Image 22 (OCR) ===\noe\n\n=== Page 5 Image 23 (OCR) ===\na\n\n=== Page 5 Image 24 (OCR) ===\nQunoue).\n\n=== Page 5 Image 26 (OCR) ===\nguaoue)\n\n=== Page 5 Image 27 (OCR) ===\na\n\n=== Page 5 Image 28 (OCR) ===\nuaoue).\n\n=== Page 5 Image 29 (OCR) ===\neuaoue).\n\n=== Page 5 Image 30 (OCR) ===\na\n\n=== Page 5 Image 31 (OCR) ===\n—\n\n=== Page 5 Image 32 (OCR) ===\noe\n\n=== Page 5 Image 33 (OCR) ===\na\n\n=== Page 5 Image 34 (OCR) ===\nQunoue).\n\n=== Page 5 Image 36 (OCR) ===\nguaoue)\n\n=== Page 5 Image 37 (OCR) ===\na\n\n=== Page 5 Image 38 (OCR) ===\nuaoue).\n\n=== Page 5 Image 39 (OCR) ===\neuaoue).\n\n=== Page 5 Image 40 (OCR) ===\na\n\n=== Page 5 Image 41 (OCR) ===\n—\n\n=== Page 5 Image 42 (OCR) ===\noe\n\n=== Page 5 Image 43 (OCR) ===\na\n\n=== Page 5 Image 44 (OCR) ===\nQunoue).\n\n=== Page 5 Image 46 (OCR) ===\nguaoue)\n\n=== Page 5 Image 47 (OCR) ===\na\n\n=== Page 5 Image 48 (OCR) ===\nuaoue).\n\n=== Page 5 Image 49 (OCR) ===\neuaoue).\n\n=== Page 5 Image 50 (OCR) ===\na\n\n=== Page 5 Image 51 (OCR) ===\n—\n\n=== Page 5 Image 52 (OCR) ===\noe\n\n=== Page 5 Image 53 (OCR) ===\na\n\n=== Page 5 Image 54 (OCR) ===\nQunoue).\n\n=== Page 5 Image 56 (OCR) ===\nguaoue)\n\n=== Page 5 Image 57 (OCR) ===\na\n\n=== Page 5 Image 58 (OCR) ===\nuaoue).\n\n=== Page 5 Image 59 (OCR) ===\neuaoue).\n\n=== Page 5 Image 60 (OCR) ===\na\n\n=== Page 5 Image 61 (OCR) ===\n—\n\n=== Page 5 Image 62 (OCR) ===\noe\n\n=== Page 5 Image 63 (OCR) ===\na\n\n=== Page 5 Image 64 (OCR) ===\nQunoue).\n\n=== Page 5 Image 66 (OCR) ===\nguaoue)\n\n=== Page 5 Image 67 (OCR) ===\na\n\n=== Page 5 Image 68 (OCR) ===\nuaoue).\n\n=== Page 5 Image 69 (OCR) ===\neuaoue).\n\n=== Page 5 Image 70 (OCR) ===\na\n\n=== Page 6 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nBACKUP\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 6 Image 1 (OCR) ===\n—\n\n=== Page 6 Image 2 (OCR) ===\noe\n\n=== Page 6 Image 3 (OCR) ===\na\n\n=== Page 6 Image 4 (OCR) ===\nQunoue).\n\n=== Page 6 Image 6 (OCR) ===\nguaoue)\n\n=== Page 6 Image 7 (OCR) ===\na\n\n=== Page 6 Image 8 (OCR) ===\nuaoue).\n\n=== Page 6 Image 9 (OCR) ===\neuaoue).\n\n=== Page 6 Image 10 (OCR) ===\na\n\n=== Page 6 Image 11 (OCR) ===\n—\n\n=== Page 6 Image 12 (OCR) ===\noe\n\n=== Page 6 Image 13 (OCR) ===\na\n\n=== Page 6 Image 14 (OCR) ===\nQunoue).\n\n=== Page 6 Image 16 (OCR) ===\nguaoue)\n\n=== Page 6 Image 17 (OCR) ===\na\n\n=== Page 6 Image 18 (OCR) ===\nuaoue).\n\n=== Page 6 Image 19 (OCR) ===\neuaoue).\n\n=== Page 6 Image 20 (OCR) ===\na\n\n=== Page 6 Image 21 (OCR) ===\n—\n\n=== Page 6 Image 22 (OCR) ===\noe\n\n=== Page 6 Image 23 (OCR) ===\na\n\n=== Page 6 Image 24 (OCR) ===\nQunoue).\n\n=== Page 6 Image 26 (OCR) ===\nguaoue)\n\n=== Page 6 Image 27 (OCR) ===\na\n\n=== Page 6 Image 28 (OCR) ===\nuaoue).\n\n=== Page 6 Image 29 (OCR) ===\neuaoue).\n\n=== Page 6 Image 30 (OCR) ===\na\n\n=== Page 6 Image 31 (OCR) ===\n—\n\n=== Page 6 Image 32 (OCR) ===\noe\n\n=== Page 6 Image 33 (OCR) ===\na\n\n=== Page 6 Image 34 (OCR) ===\nQunoue).\n\n=== Page 6 Image 36 (OCR) ===\nguaoue)\n\n=== Page 6 Image 37 (OCR) ===\na\n\n=== Page 6 Image 38 (OCR) ===\nuaoue).\n\n=== Page 6 Image 39 (OCR) ===\neuaoue).\n\n=== Page 6 Image 40 (OCR) ===\na\n\n=== Page 6 Image 41 (OCR) ===\n—\n\n=== Page 6 Image 42 (OCR) ===\noe\n\n=== Page 6 Image 43 (OCR) ===\na\n\n=== Page 6 Image 44 (OCR) ===\nQunoue).\n\n=== Page 6 Image 46 (OCR) ===\nguaoue)\n\n=== Page 6 Image 47 (OCR) ===\na\n\n=== Page 6 Image 48 (OCR) ===\nuaoue).\n\n=== Page 6 Image 49 (OCR) ===\neuaoue).\n\n=== Page 6 Image 50 (OCR) ===\na\n\n=== Page 6 Image 51 (OCR) ===\n—\n\n=== Page 6 Image 52 (OCR) ===\noe\n\n=== Page 6 Image 53 (OCR) ===\na\n\n=== Page 6 Image 54 (OCR) ===\nQunoue).\n\n=== Page 6 Image 56 (OCR) ===\nguaoue)\n\n=== Page 6 Image 57 (OCR) ===\na\n\n=== Page 6 Image 58 (OCR) ===\nuaoue).\n\n=== Page 6 Image 59 (OCR) ===\neuaoue).\n\n=== Page 6 Image 60 (OCR) ===\na\n\n=== Page 6 Image 61 (OCR) ===\n—\n\n=== Page 6 Image 62 (OCR) ===\noe\n\n=== Page 6 Image 63 (OCR) ===\na\n\n=== Page 6 Image 64 (OCR) ===\nQunoue).\n\n=== Page 6 Image 66 (OCR) ===\nguaoue)\n\n=== Page 6 Image 67 (OCR) ===\na\n\n=== Page 6 Image 68 (OCR) ===\nuaoue).\n\n=== Page 6 Image 69 (OCR) ===\neuaoue).\n\n=== Page 6 Image 70 (OCR) ===\na\n\n=== Page 7 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nAssessment of current performance of Collegium\nCollegium strategy going forward: key ingoing assumptions\n• 2 product portfolio exclusively in pain management therapeutic area, with \nR&D pipeline all early life (Ph II or earlier) and concentrated in pain \nmanagement1\n• Facing “finite” market for its current portfolio, driven by:\n– Overall U.S. ERO market continuing to decline (-15% YoY decline2 until \n2020)\n– Likely genericization of extended-release oxycodone with abuse-deterrent \nformulations, leading to a market shift away from branded opioids\n• Product portfolio is facing challenges\n– Xtampza ER (oxycodone): $50.9M sales in Q1-Q3 20182\n• Competing with an established market leader in a highly genericized class\n– Nucynta (tapentadol): $156M sales in Q1-Q3 20182\n• Slow launch since acquisition and experiencing share loss (-4% TRx from \nQ2-Q3 ’18)\n• Collegium responsible for minimum $135M/yr royalty payment for first 4 \nyears of licensing regardless of product performance\n• Collegium continues to invest in salesforce reps (~150) calling on specialists \n(~10,700) for both products\n• Overall, Collegium is unprofitable ($31M loss from operations Q1-Q3 2018)\n– ($0.50) EPS for Q3 ’18, missing Thomson Reuters’ consensus estimate of \n($0 36)\n1 Collegium has one preclinical ADHD molecule\n2 Based on Purdue internal projection\n3 Based on Collegium 2018 Q3 10-Q \n• Given finite market \noutlook and Collegium’s \nneed to quickly return to \nprofitability, there are 2 \npotential strategic \nchoices:\n– Reduce cost by \ndownsizing salesforces, \nwhich could potentially \nlower expected sales \ngrowth\n– Augment volume with \naggressive bidding \nSOURCE: SEC filings, Internal research\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 7 Image 1 (OCR) ===\n—\n\n=== Page 7 Image 2 (OCR) ===\noe\n\n=== Page 7 Image 3 (OCR) ===\na\n\n=== Page 7 Image 4 (OCR) ===\nQunoue).\n\n=== Page 7 Image 6 (OCR) ===\nguaoue)\n\n=== Page 7 Image 7 (OCR) ===\na\n\n=== Page 7 Image 8 (OCR) ===\nuaoue).\n\n=== Page 7 Image 9 (OCR) ===\neuaoue).\n\n=== Page 7 Image 10 (OCR) ===\na\n\n=== Page 7 Image 11 (OCR) ===\n—\n\n=== Page 7 Image 12 (OCR) ===\noe\n\n=== Page 7 Image 13 (OCR) ===\na\n\n=== Page 7 Image 14 (OCR) ===\nQunoue).\n\n=== Page 7 Image 16 (OCR) ===\nguaoue)\n\n=== Page 7 Image 17 (OCR) ===\na\n\n=== Page 7 Image 18 (OCR) ===\nuaoue).\n\n=== Page 7 Image 19 (OCR) ===\neuaoue).\n\n=== Page 7 Image 20 (OCR) ===\na\n\n=== Page 7 Image 21 (OCR) ===\n—\n\n=== Page 7 Image 22 (OCR) ===\noe\n\n=== Page 7 Image 23 (OCR) ===\na\n\n=== Page 7 Image 24 (OCR) ===\nQunoue).\n\n=== Page 7 Image 26 (OCR) ===\nguaoue)\n\n=== Page 7 Image 27 (OCR) ===\na\n\n=== Page 7 Image 28 (OCR) ===\nuaoue).\n\n=== Page 7 Image 29 (OCR) ===\neuaoue).\n\n=== Page 7 Image 30 (OCR) ===\na\n\n=== Page 7 Image 31 (OCR) ===\n—\n\n=== Page 7 Image 32 (OCR) ===\noe\n\n=== Page 7 Image 33 (OCR) ===\na\n\n=== Page 7 Image 34 (OCR) ===\nQunoue).\n\n=== Page 7 Image 36 (OCR) ===\nguaoue)\n\n=== Page 7 Image 37 (OCR) ===\na\n\n=== Page 7 Image 38 (OCR) ===\nuaoue).\n\n=== Page 7 Image 39 (OCR) ===\neuaoue).\n\n=== Page 7 Image 40 (OCR) ===\na\n\n=== Page 7 Image 41 (OCR) ===\n—\n\n=== Page 7 Image 42 (OCR) ===\noe\n\n=== Page 7 Image 43 (OCR) ===\na\n\n=== Page 7 Image 44 (OCR) ===\nQunoue).\n\n=== Page 7 Image 46 (OCR) ===\nguaoue)\n\n=== Page 7 Image 47 (OCR) ===\na\n\n=== Page 7 Image 48 (OCR) ===\nuaoue).\n\n=== Page 7 Image 49 (OCR) ===\neuaoue).\n\n=== Page 7 Image 50 (OCR) ===\na\n\n=== Page 7 Image 51 (OCR) ===\n—\n\n=== Page 7 Image 52 (OCR) ===\noe\n\n=== Page 7 Image 53 (OCR) ===\na\n\n=== Page 7 Image 54 (OCR) ===\nQunoue).\n\n=== Page 7 Image 56 (OCR) ===\nguaoue)\n\n=== Page 7 Image 57 (OCR) ===\na\n\n=== Page 7 Image 58 (OCR) ===\nuaoue).\n\n=== Page 7 Image 59 (OCR) ===\neuaoue).\n\n=== Page 7 Image 60 (OCR) ===\na\n\n=== Page 7 Image 61 (OCR) ===\n—\n\n=== Page 7 Image 62 (OCR) ===\noe\n\n=== Page 7 Image 63 (OCR) ===\na\n\n=== Page 7 Image 64 (OCR) ===\nQunoue).\n\n=== Page 7 Image 66 (OCR) ===\nguaoue)\n\n=== Page 7 Image 67 (OCR) ===\na\n\n=== Page 7 Image 68 (OCR) ===\nuaoue).\n\n=== Page 7 Image 69 (OCR) ===\neuaoue).\n\n=== Page 7 Image 70 (OCR) ===\na\n\n=== Page 8 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent view of Collegium profitability\n452\n217\n174\n172\n63\n70\n182\n80\n-32\nGross sales\nLoss \nfrom \noperati\nons\nRebates\nOther \nGTN \nreductio\nns\nNet sales\n9\nCOGS\nR&D\nSG&A\n24\n252\n626\n88\n287\n128\n32\nXtampza\nNucynta\nOverall \nRevenue and GTN \nreductions\nCosts and operating \nexpenses\n2018 financial performance (estimation) \n($ Millions)\n• Cash at the end of \nQ3 2018:  ~$140 \nMn\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 8 Image 1 (OCR) ===\n—\n\n=== Page 8 Image 2 (OCR) ===\noe\n\n=== Page 8 Image 3 (OCR) ===\na\n\n=== Page 8 Image 4 (OCR) ===\nQunoue).\n\n=== Page 8 Image 6 (OCR) ===\nguaoue)\n\n=== Page 8 Image 7 (OCR) ===\na\n\n=== Page 8 Image 8 (OCR) ===\nuaoue).\n\n=== Page 8 Image 9 (OCR) ===\neuaoue).\n\n=== Page 8 Image 10 (OCR) ===\na\n\n=== Page 8 Image 11 (OCR) ===\n—\n\n=== Page 8 Image 12 (OCR) ===\noe\n\n=== Page 8 Image 13 (OCR) ===\na\n\n=== Page 8 Image 14 (OCR) ===\nQunoue).\n\n=== Page 8 Image 16 (OCR) ===\nguaoue)\n\n=== Page 8 Image 17 (OCR) ===\na\n\n=== Page 8 Image 18 (OCR) ===\nuaoue).\n\n=== Page 8 Image 19 (OCR) ===\neuaoue).\n\n=== Page 8 Image 20 (OCR) ===\na\n\n=== Page 8 Image 21 (OCR) ===\n—\n\n=== Page 8 Image 22 (OCR) ===\noe\n\n=== Page 8 Image 23 (OCR) ===\na\n\n=== Page 8 Image 24 (OCR) ===\nQunoue).\n\n=== Page 8 Image 26 (OCR) ===\nguaoue)\n\n=== Page 8 Image 27 (OCR) ===\na\n\n=== Page 8 Image 28 (OCR) ===\nuaoue).\n\n=== Page 8 Image 29 (OCR) ===\neuaoue).\n\n=== Page 8 Image 30 (OCR) ===\na\n\n=== Page 8 Image 31 (OCR) ===\n—\n\n=== Page 8 Image 32 (OCR) ===\noe\n\n=== Page 8 Image 33 (OCR) ===\na\n\n=== Page 8 Image 34 (OCR) ===\nQunoue).\n\n=== Page 8 Image 36 (OCR) ===\nguaoue)\n\n=== Page 8 Image 37 (OCR) ===\na\n\n=== Page 8 Image 38 (OCR) ===\nuaoue).\n\n=== Page 8 Image 39 (OCR) ===\neuaoue).\n\n=== Page 8 Image 40 (OCR) ===\na\n\n=== Page 8 Image 41 (OCR) ===\n—\n\n=== Page 8 Image 42 (OCR) ===\noe\n\n=== Page 8 Image 43 (OCR) ===\na\n\n=== Page 8 Image 44 (OCR) ===\nQunoue).\n\n=== Page 8 Image 46 (OCR) ===\nguaoue)\n\n=== Page 8 Image 47 (OCR) ===\na\n\n=== Page 8 Image 48 (OCR) ===\nuaoue).\n\n=== Page 8 Image 49 (OCR) ===\neuaoue).\n\n=== Page 8 Image 50 (OCR) ===\na\n\n=== Page 8 Image 51 (OCR) ===\n—\n\n=== Page 8 Image 52 (OCR) ===\noe\n\n=== Page 8 Image 53 (OCR) ===\na\n\n=== Page 8 Image 54 (OCR) ===\nQunoue).\n\n=== Page 8 Image 56 (OCR) ===\nguaoue)\n\n=== Page 8 Image 57 (OCR) ===\na\n\n=== Page 8 Image 58 (OCR) ===\nuaoue).\n\n=== Page 8 Image 59 (OCR) ===\neuaoue).\n\n=== Page 8 Image 60 (OCR) ===\na\n\n=== Page 8 Image 61 (OCR) ===\n—\n\n=== Page 8 Image 62 (OCR) ===\noe\n\n=== Page 8 Image 63 (OCR) ===\na\n\n=== Page 8 Image 64 (OCR) ===\nQunoue).\n\n=== Page 8 Image 66 (OCR) ===\nguaoue)\n\n=== Page 8 Image 67 (OCR) ===\na\n\n=== Page 8 Image 68 (OCR) ===\nuaoue).\n\n=== Page 8 Image 69 (OCR) ===\neuaoue).\n\n=== Page 8 Image 70 (OCR) ===\na\n\n=== Page 9 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium would need to double current share of Xtampza in order to break even\n9\nPotential impact of doubling Xtampza share through exclusive contracts with additional payors\n14\nCurrent loss \nfrom \noperations\n2020 \noperating \nincome\nLoss due to \nmarket \ndecline\nGrowth from \nexisting \naccount\nGrowth \nfrom new \naccount\nCOGS increase\n0\n32\n19\n15\n50\nKey \nassumptions:\n• ERO market \ncontinues to \ndecline at -15% \nyear on year \nuntil 2020\n• GtN of sales with \nnew account: \n60%\n• Nucynta sales \nremains the \nsame\n• SG&A remains \nthe same\nProjected 2020 Xtampza  financial performance \n($ Millions)\nDIRECTIONAL ESTIMATION\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 9 Image 1 (OCR) ===\n—\n\n=== Page 9 Image 2 (OCR) ===\noe\n\n=== Page 9 Image 3 (OCR) ===\na\n\n=== Page 9 Image 4 (OCR) ===\nQunoue).\n\n=== Page 9 Image 6 (OCR) ===\nguaoue)\n\n=== Page 9 Image 7 (OCR) ===\na\n\n=== Page 9 Image 8 (OCR) ===\nuaoue).\n\n=== Page 9 Image 9 (OCR) ===\neuaoue).\n\n=== Page 9 Image 10 (OCR) ===\na\n\n=== Page 9 Image 11 (OCR) ===\n—\n\n=== Page 9 Image 12 (OCR) ===\noe\n\n=== Page 9 Image 13 (OCR) ===\na\n\n=== Page 9 Image 14 (OCR) ===\nQunoue).\n\n=== Page 9 Image 16 (OCR) ===\nguaoue)\n\n=== Page 9 Image 17 (OCR) ===\na\n\n=== Page 9 Image 18 (OCR) ===\nuaoue).\n\n=== Page 9 Image 19 (OCR) ===\neuaoue).\n\n=== Page 9 Image 20 (OCR) ===\na\n\n=== Page 9 Image 21 (OCR) ===\n—\n\n=== Page 9 Image 22 (OCR) ===\noe\n\n=== Page 9 Image 23 (OCR) ===\na\n\n=== Page 9 Image 24 (OCR) ===\nQunoue).\n\n=== Page 9 Image 26 (OCR) ===\nguaoue)\n\n=== Page 9 Image 27 (OCR) ===\na\n\n=== Page 9 Image 28 (OCR) ===\nuaoue).\n\n=== Page 9 Image 29 (OCR) ===\neuaoue).\n\n=== Page 9 Image 30 (OCR) ===\na\n\n=== Page 9 Image 31 (OCR) ===\n—\n\n=== Page 9 Image 32 (OCR) ===\noe\n\n=== Page 9 Image 33 (OCR) ===\na\n\n=== Page 9 Image 34 (OCR) ===\nQunoue).\n\n=== Page 9 Image 36 (OCR) ===\nguaoue)\n\n=== Page 9 Image 37 (OCR) ===\na\n\n=== Page 9 Image 38 (OCR) ===\nuaoue).\n\n=== Page 9 Image 39 (OCR) ===\neuaoue).\n\n=== Page 9 Image 40 (OCR) ===\na\n\n=== Page 9 Image 41 (OCR) ===\n—\n\n=== Page 9 Image 42 (OCR) ===\noe\n\n=== Page 9 Image 43 (OCR) ===\na\n\n=== Page 9 Image 44 (OCR) ===\nQunoue).\n\n=== Page 9 Image 46 (OCR) ===\nguaoue)\n\n=== Page 9 Image 47 (OCR) ===\na\n\n=== Page 9 Image 48 (OCR) ===\nuaoue).\n\n=== Page 9 Image 49 (OCR) ===\neuaoue).\n\n=== Page 9 Image 50 (OCR) ===\na\n\n=== Page 9 Image 51 (OCR) ===\n—\n\n=== Page 9 Image 52 (OCR) ===\noe\n\n=== Page 9 Image 53 (OCR) ===\na\n\n=== Page 9 Image 54 (OCR) ===\nQunoue).\n\n=== Page 9 Image 56 (OCR) ===\nguaoue)\n\n=== Page 9 Image 57 (OCR) ===\na\n\n=== Page 9 Image 58 (OCR) ===\nuaoue).\n\n=== Page 9 Image 59 (OCR) ===\neuaoue).\n\n=== Page 9 Image 60 (OCR) ===\na\n\n=== Page 9 Image 61 (OCR) ===\n—\n\n=== Page 9 Image 62 (OCR) ===\noe\n\n=== Page 9 Image 63 (OCR) ===\na\n\n=== Page 9 Image 64 (OCR) ===\nQunoue).\n\n=== Page 9 Image 66 (OCR) ===\nguaoue)\n\n=== Page 9 Image 67 (OCR) ===\na\n\n=== Page 9 Image 68 (OCR) ===\nuaoue).\n\n=== Page 9 Image 69 (OCR) ===\neuaoue).\n\n=== Page 9 Image 70 (OCR) ===\na\n\n=== Page 10 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nOverview of top accounts across Commercial and Medicare: current view\n10\nNet sales1\n$M\nMarket \nsegment\nCommer-\ncial\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\n112\n992\n193\n21\n102\n26\n21\n7\n12\n11\n6\n258\n155\n26\n20\n8\n5\n10\n73\n17\n18\n113\n63\n15\n9\n6\n6\n113\n13\n17\n53\n5\n4\n545\n2019 contracting\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for those accounts with OxyContin formulary access, status based on majority of lives; 4 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other \nprime accounts \nAccount\nExpress Scripts\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC4\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nGross sales\n$M \nMarket \nShare\n% \nNet sales \nOxyContin\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\nMedImpact\n2T Preferred\nRebate2\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nCollegium is \nlikely to \ndouble \ndown on big \nnational \naccounts in \norder to \nachieve \nbreak-even\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 10 Image 1 (OCR) ===\n—\n\n=== Page 10 Image 2 (OCR) ===\noe\n\n=== Page 10 Image 3 (OCR) ===\na\n\n=== Page 10 Image 4 (OCR) ===\nQunoue).\n\n=== Page 10 Image 6 (OCR) ===\nguaoue)\n\n=== Page 10 Image 7 (OCR) ===\na\n\n=== Page 10 Image 8 (OCR) ===\nuaoue).\n\n=== Page 10 Image 9 (OCR) ===\neuaoue).\n\n=== Page 10 Image 10 (OCR) ===\na\n\n=== Page 10 Image 11 (OCR) ===\n—\n\n=== Page 10 Image 12 (OCR) ===\noe\n\n=== Page 10 Image 13 (OCR) ===\na\n\n=== Page 10 Image 14 (OCR) ===\nQunoue).\n\n=== Page 10 Image 16 (OCR) ===\nguaoue)\n\n=== Page 10 Image 17 (OCR) ===\na\n\n=== Page 10 Image 18 (OCR) ===\nuaoue).\n\n=== Page 10 Image 19 (OCR) ===\neuaoue).\n\n=== Page 10 Image 20 (OCR) ===\na\n\n=== Page 10 Image 21 (OCR) ===\n—\n\n=== Page 10 Image 22 (OCR) ===\noe\n\n=== Page 10 Image 23 (OCR) ===\na\n\n=== Page 10 Image 24 (OCR) ===\nQunoue).\n\n=== Page 10 Image 26 (OCR) ===\nguaoue)\n\n=== Page 10 Image 27 (OCR) ===\na\n\n=== Page 10 Image 28 (OCR) ===\nuaoue).\n\n=== Page 10 Image 29 (OCR) ===\neuaoue).\n\n=== Page 10 Image 30 (OCR) ===\na\n\n=== Page 10 Image 31 (OCR) ===\n—\n\n=== Page 10 Image 32 (OCR) ===\noe\n\n=== Page 10 Image 33 (OCR) ===\na\n\n=== Page 10 Image 34 (OCR) ===\nQunoue).\n\n=== Page 10 Image 36 (OCR) ===\nguaoue)\n\n=== Page 10 Image 37 (OCR) ===\na\n\n=== Page 10 Image 38 (OCR) ===\nuaoue).\n\n=== Page 10 Image 39 (OCR) ===\neuaoue).\n\n=== Page 10 Image 40 (OCR) ===\na\n\n=== Page 10 Image 41 (OCR) ===\n—\n\n=== Page 10 Image 42 (OCR) ===\noe\n\n=== Page 10 Image 43 (OCR) ===\na\n\n=== Page 10 Image 44 (OCR) ===\nQunoue).\n\n=== Page 10 Image 46 (OCR) ===\nguaoue)\n\n=== Page 10 Image 47 (OCR) ===\na\n\n=== Page 10 Image 48 (OCR) ===\nuaoue).\n\n=== Page 10 Image 49 (OCR) ===\neuaoue).\n\n=== Page 10 Image 50 (OCR) ===\na\n\n=== Page 10 Image 51 (OCR) ===\n—\n\n=== Page 10 Image 52 (OCR) ===\noe\n\n=== Page 10 Image 53 (OCR) ===\na\n\n=== Page 10 Image 54 (OCR) ===\nQunoue).\n\n=== Page 10 Image 56 (OCR) ===\nguaoue)\n\n=== Page 10 Image 57 (OCR) ===\na\n\n=== Page 10 Image 58 (OCR) ===\nuaoue).\n\n=== Page 10 Image 59 (OCR) ===\neuaoue).\n\n=== Page 10 Image 60 (OCR) ===\na\n\n=== Page 10 Image 61 (OCR) ===\n—\n\n=== Page 10 Image 62 (OCR) ===\noe\n\n=== Page 10 Image 63 (OCR) ===\na\n\n=== Page 10 Image 64 (OCR) ===\nQunoue).\n\n=== Page 10 Image 66 (OCR) ===\nguaoue)\n\n=== Page 10 Image 67 (OCR) ===\na\n\n=== Page 10 Image 68 (OCR) ===\nuaoue).\n\n=== Page 10 Image 69 (OCR) ===\neuaoue).\n\n=== Page 10 Image 70 (OCR) ===\na\n\n=== Page 11 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent access status: OxyContin is preferred for 47% of lives on Prime’s Part D formularies\n11\nSOURCE: MMIT\n• OxyContin is the preferred oxycodone with access to nearly half of Prime lives while Xtampza ER is excluded\n• Zohydro ER is the preferred branded hydrocodone product (Hysingla ER is completely excluded), and Nucynta also maintains access \nto half of Prime lives\n531\n94\n8\n26\n575\n25552\nPrivileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal \nand regulatory review before they can be considered final. These materials are confidential and proprietary.\n1 Includes ~10K lives where no PA/ST required for OxyContin and Nucynta\n2 Defined as percentage of lives that are either preferred or covered (including PA/ST)\nLives, K\nOverall formulary \nstatus\nLives, \n%\nHysingl\na ER\nXtampz\na ER\nOxyCo\nntin\nNucynt\na ER\nZohydr\no ER\n1,235\nOverall covered \nlives %2\n0%\n0%\n47%\n47%\n92%\nLargest formulary\n47\n%\nCollegium \nexcluded1 \nNot \nCovered\nNot \nCovered\nPreferre\nd \n(PA/ST)\nPreferred \n(PA/ST)\nCovered \n(PA/ST)\nBCBS FL BlueMedicare Classic \nand Choice \n43%\nOnly Zohydro - \ncovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST) \nHISC Blue Medicare Rx (PDP) \nPlus and Value \n8%\nNo branded ERO \ncoverage\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nRegence BCBS of Oregon \nMedAdvantage + RxClassic PPO \n+ RxEnhanced PPO \n2%\nOnly Zohydro - \npreferred\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nPreferred \n(PA/ST)\nBlue Cross Community MMAI \n1\n%\nOxyContin and \nZohydro \npreferred\nNot \nCovered\nNot \nCovered\nPreferre\nd \n(PA/ST)\nNot \nCovered\nPreferred \n(PA/ST)\nBlue Cross Blue Shield of \nMinnesota SecureBlue \nCoverage status of leading ERO brands, \nNov 2018\nPRIME\nTotal\nOxycontin Covered\nNot covered\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 11 Image 1 (OCR) ===\n—\n\n=== Page 11 Image 2 (OCR) ===\noe\n\n=== Page 11 Image 3 (OCR) ===\na\n\n=== Page 11 Image 4 (OCR) ===\nQunoue).\n\n=== Page 11 Image 6 (OCR) ===\nguaoue)\n\n=== Page 11 Image 7 (OCR) ===\na\n\n=== Page 11 Image 8 (OCR) ===\nuaoue).\n\n=== Page 11 Image 9 (OCR) ===\neuaoue).\n\n=== Page 11 Image 10 (OCR) ===\na\n\n=== Page 11 Image 11 (OCR) ===\n—\n\n=== Page 11 Image 12 (OCR) ===\noe\n\n=== Page 11 Image 13 (OCR) ===\na\n\n=== Page 11 Image 14 (OCR) ===\nQunoue).\n\n=== Page 11 Image 16 (OCR) ===\nguaoue)\n\n=== Page 11 Image 17 (OCR) ===\na\n\n=== Page 11 Image 18 (OCR) ===\nuaoue).\n\n=== Page 11 Image 19 (OCR) ===\neuaoue).\n\n=== Page 11 Image 20 (OCR) ===\na\n\n=== Page 11 Image 21 (OCR) ===\n—\n\n=== Page 11 Image 22 (OCR) ===\noe\n\n=== Page 11 Image 23 (OCR) ===\na\n\n=== Page 11 Image 24 (OCR) ===\nQunoue).\n\n=== Page 11 Image 26 (OCR) ===\nguaoue)\n\n=== Page 11 Image 27 (OCR) ===\na\n\n=== Page 11 Image 28 (OCR) ===\nuaoue).\n\n=== Page 11 Image 29 (OCR) ===\neuaoue).\n\n=== Page 11 Image 30 (OCR) ===\na\n\n=== Page 11 Image 31 (OCR) ===\n—\n\n=== Page 11 Image 32 (OCR) ===\noe\n\n=== Page 11 Image 33 (OCR) ===\na\n\n=== Page 11 Image 34 (OCR) ===\nQunoue).\n\n=== Page 11 Image 36 (OCR) ===\nguaoue)\n\n=== Page 11 Image 37 (OCR) ===\na\n\n=== Page 11 Image 38 (OCR) ===\nuaoue).\n\n=== Page 11 Image 39 (OCR) ===\neuaoue).\n\n=== Page 11 Image 40 (OCR) ===\na\n\n=== Page 11 Image 41 (OCR) ===\n—\n\n=== Page 11 Image 42 (OCR) ===\noe\n\n=== Page 11 Image 43 (OCR) ===\na\n\n=== Page 11 Image 44 (OCR) ===\nQunoue).\n\n=== Page 11 Image 46 (OCR) ===\nguaoue)\n\n=== Page 11 Image 47 (OCR) ===\na\n\n=== Page 11 Image 48 (OCR) ===\nuaoue).\n\n=== Page 11 Image 49 (OCR) ===\neuaoue).\n\n=== Page 11 Image 50 (OCR) ===\na\n\n=== Page 11 Image 51 (OCR) ===\n—\n\n=== Page 11 Image 52 (OCR) ===\noe\n\n=== Page 11 Image 53 (OCR) ===\na\n\n=== Page 11 Image 54 (OCR) ===\nQunoue).\n\n=== Page 11 Image 56 (OCR) ===\nguaoue)\n\n=== Page 11 Image 57 (OCR) ===\na\n\n=== Page 11 Image 58 (OCR) ===\nuaoue).\n\n=== Page 11 Image 59 (OCR) ===\neuaoue).\n\n=== Page 11 Image 60 (OCR) ===\na\n\n=== Page 11 Image 61 (OCR) ===\n—\n\n=== Page 11 Image 62 (OCR) ===\noe\n\n=== Page 11 Image 63 (OCR) ===\na\n\n=== Page 11 Image 64 (OCR) ===\nQunoue).\n\n=== Page 11 Image 66 (OCR) ===\nguaoue)\n\n=== Page 11 Image 67 (OCR) ===\na\n\n=== Page 11 Image 68 (OCR) ===\nuaoue).\n\n=== Page 11 Image 69 (OCR) ===\neuaoue).\n\n=== Page 11 Image 70 (OCR) ===\na\n\n=== Page 12 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe defined potential 2020 access scenarios for Oxycontin vs. Xtampza\n2020 Share shift assumptions under different scenarios, 2020 Q4 \n2020 access \nscenarios\nContinue current \naccess status as \nexclusive preferred \noxycodone ER\n1\n1\n1\n2\n3\n15\n18\n7\n14\n4\n4\n10\n4\n4\n10\n6\n5\n5\n6\n7\n5\n8\n4\n18\n18\n18\n18\n18\n18\nOxycontin\nOther brands\nXtampza\nShare by products (exit share) \nShare shift vs. \nstatus quo \nXtampza covered \n(non-preferred), \nwhile OxyContin \nstays preferred\n2\nLow\nHig\nh\n5%\n35%\nXtampza replaces \nOxycontin as \nexclusive preferred \nwith \ngrandfathering\n3\nLow\nHig\nh\n35%\n55%\nOxycontin Excluded \nwithout \ngrandfathering\n4\nLow\nHig\nh\n50%\n70%\n0%\nENVISION\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 12 Image 1 (OCR) ===\n—\n\n=== Page 12 Image 2 (OCR) ===\noe\n\n=== Page 12 Image 3 (OCR) ===\na\n\n=== Page 12 Image 4 (OCR) ===\nQunoue).\n\n=== Page 12 Image 6 (OCR) ===\nguaoue)\n\n=== Page 12 Image 7 (OCR) ===\na\n\n=== Page 12 Image 8 (OCR) ===\nuaoue).\n\n=== Page 12 Image 9 (OCR) ===\neuaoue).\n\n=== Page 12 Image 10 (OCR) ===\na\n\n=== Page 12 Image 11 (OCR) ===\n—\n\n=== Page 12 Image 12 (OCR) ===\noe\n\n=== Page 12 Image 13 (OCR) ===\na\n\n=== Page 12 Image 14 (OCR) ===\nQunoue).\n\n=== Page 12 Image 16 (OCR) ===\nguaoue)\n\n=== Page 12 Image 17 (OCR) ===\na\n\n=== Page 12 Image 18 (OCR) ===\nuaoue).\n\n=== Page 12 Image 19 (OCR) ===\neuaoue).\n\n=== Page 12 Image 20 (OCR) ===\na\n\n=== Page 12 Image 21 (OCR) ===\n—\n\n=== Page 12 Image 22 (OCR) ===\noe\n\n=== Page 12 Image 23 (OCR) ===\na\n\n=== Page 12 Image 24 (OCR) ===\nQunoue).\n\n=== Page 12 Image 26 (OCR) ===\nguaoue)\n\n=== Page 12 Image 27 (OCR) ===\na\n\n=== Page 12 Image 28 (OCR) ===\nuaoue).\n\n=== Page 12 Image 29 (OCR) ===\neuaoue).\n\n=== Page 12 Image 30 (OCR) ===\na\n\n=== Page 12 Image 31 (OCR) ===\n—\n\n=== Page 12 Image 32 (OCR) ===\noe\n\n=== Page 12 Image 33 (OCR) ===\na\n\n=== Page 12 Image 34 (OCR) ===\nQunoue).\n\n=== Page 12 Image 36 (OCR) ===\nguaoue)\n\n=== Page 12 Image 37 (OCR) ===\na\n\n=== Page 12 Image 38 (OCR) ===\nuaoue).\n\n=== Page 12 Image 39 (OCR) ===\neuaoue).\n\n=== Page 12 Image 40 (OCR) ===\na\n\n=== Page 12 Image 41 (OCR) ===\n—\n\n=== Page 12 Image 42 (OCR) ===\noe\n\n=== Page 12 Image 43 (OCR) ===\na\n\n=== Page 12 Image 44 (OCR) ===\nQunoue).\n\n=== Page 12 Image 46 (OCR) ===\nguaoue)\n\n=== Page 12 Image 47 (OCR) ===\na\n\n=== Page 12 Image 48 (OCR) ===\nuaoue).\n\n=== Page 12 Image 49 (OCR) ===\neuaoue).\n\n=== Page 12 Image 50 (OCR) ===\na\n\n=== Page 12 Image 51 (OCR) ===\n—\n\n=== Page 12 Image 52 (OCR) ===\noe\n\n=== Page 12 Image 53 (OCR) ===\na\n\n=== Page 12 Image 54 (OCR) ===\nQunoue).\n\n=== Page 12 Image 56 (OCR) ===\nguaoue)\n\n=== Page 12 Image 57 (OCR) ===\na\n\n=== Page 12 Image 58 (OCR) ===\nuaoue).\n\n=== Page 12 Image 59 (OCR) ===\neuaoue).\n\n=== Page 12 Image 60 (OCR) ===\na\n\n=== Page 12 Image 61 (OCR) ===\n—\n\n=== Page 12 Image 62 (OCR) ===\noe\n\n=== Page 12 Image 63 (OCR) ===\na\n\n=== Page 12 Image 64 (OCR) ===\nQunoue).\n\n=== Page 12 Image 66 (OCR) ===\nguaoue)\n\n=== Page 12 Image 67 (OCR) ===\na\n\n=== Page 12 Image 68 (OCR) ===\nuaoue).\n\n=== Page 12 Image 69 (OCR) ===\neuaoue).\n\n=== Page 12 Image 70 (OCR) ===\na\n\n=== Page 13 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering \n5.9\n6.8\n6.8\n6.2\n4.9\n5.8\n4.8\n4.4\nAccess \nscenarios tested\nXtampza \ncovered (non-\npreferred), \nwhile \nOxyContin \nstays \npreferred\nContinue \ncurrent \naccess status \nas exclusive \npreferred \noxycodone ER\nXtampza \nreplaces \nOxycontin as \nexclusive \npreferred with \ngrandfatherin\ngOxycontin \nExcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n0%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\ns to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. \n0.5\n0.2\n0.7\n0.4\n0.5\n0.7\nShare by \nproduct\nOther brand \nnet sales \n($M)\n4\n5\n3\n4\n1\n14\n4\n4\n10\n4\n10\n5\n6\n7\n7\n5\n6\n8\n4\n18\n18\n18\n18\n18\n17\n2.1\n1.4\n1.9\n1.9\n2.2\n2.4\nOxycontin\nXtampza\nOther brands\nSha\nre \nshif\nt\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nENVISION\n15\n2\n1 18\n0.7\n0.8\n46%\nBreak-\neven \nrebate2 \n31%\n35%\nN/A\n13%\n33%\nNet sales at min \nrebate ($M)\nRebate rate to keep \nEnvision whole1 \n32%\n22%\n29%\nN/A\n8%\n10%\n24%\nTheoretic\nal – \nunlikely \nable to \nlower \ncurrent \nrate \n(40%)\n16%\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 13 Image 1 (OCR) ===\n—\n\n=== Page 13 Image 2 (OCR) ===\noe\n\n=== Page 13 Image 3 (OCR) ===\na\n\n=== Page 13 Image 4 (OCR) ===\nQunoue).\n\n=== Page 13 Image 6 (OCR) ===\nguaoue)\n\n=== Page 13 Image 7 (OCR) ===\na\n\n=== Page 13 Image 8 (OCR) ===\nuaoue).\n\n=== Page 13 Image 9 (OCR) ===\neuaoue).\n\n=== Page 13 Image 10 (OCR) ===\na\n\n=== Page 13 Image 11 (OCR) ===\n—\n\n=== Page 13 Image 12 (OCR) ===\noe\n\n=== Page 13 Image 13 (OCR) ===\na\n\n=== Page 13 Image 14 (OCR) ===\nQunoue).\n\n=== Page 13 Image 16 (OCR) ===\nguaoue)\n\n=== Page 13 Image 17 (OCR) ===\na\n\n=== Page 13 Image 18 (OCR) ===\nuaoue).\n\n=== Page 13 Image 19 (OCR) ===\neuaoue).\n\n=== Page 13 Image 20 (OCR) ===\na\n\n=== Page 13 Image 21 (OCR) ===\n—\n\n=== Page 13 Image 22 (OCR) ===\noe\n\n=== Page 13 Image 23 (OCR) ===\na\n\n=== Page 13 Image 24 (OCR) ===\nQunoue).\n\n=== Page 13 Image 26 (OCR) ===\nguaoue)\n\n=== Page 13 Image 27 (OCR) ===\na\n\n=== Page 13 Image 28 (OCR) ===\nuaoue).\n\n=== Page 13 Image 29 (OCR) ===\neuaoue).\n\n=== Page 13 Image 30 (OCR) ===\na\n\n=== Page 13 Image 31 (OCR) ===\n—\n\n=== Page 13 Image 32 (OCR) ===\noe\n\n=== Page 13 Image 33 (OCR) ===\na\n\n=== Page 13 Image 34 (OCR) ===\nQunoue).\n\n=== Page 13 Image 36 (OCR) ===\nguaoue)\n\n=== Page 13 Image 37 (OCR) ===\na\n\n=== Page 13 Image 38 (OCR) ===\nuaoue).\n\n=== Page 13 Image 39 (OCR) ===\neuaoue).\n\n=== Page 13 Image 40 (OCR) ===\na\n\n=== Page 13 Image 41 (OCR) ===\n—\n\n=== Page 13 Image 42 (OCR) ===\noe\n\n=== Page 13 Image 43 (OCR) ===\na\n\n=== Page 13 Image 44 (OCR) ===\nQunoue).\n\n=== Page 13 Image 46 (OCR) ===\nguaoue)\n\n=== Page 13 Image 47 (OCR) ===\na\n\n=== Page 13 Image 48 (OCR) ===\nuaoue).\n\n=== Page 13 Image 49 (OCR) ===\neuaoue).\n\n=== Page 13 Image 50 (OCR) ===\na\n\n=== Page 13 Image 51 (OCR) ===\n—\n\n=== Page 13 Image 52 (OCR) ===\noe\n\n=== Page 13 Image 53 (OCR) ===\na\n\n=== Page 13 Image 54 (OCR) ===\nQunoue).\n\n=== Page 13 Image 56 (OCR) ===\nguaoue)\n\n=== Page 13 Image 57 (OCR) ===\na\n\n=== Page 13 Image 58 (OCR) ===\nuaoue).\n\n=== Page 13 Image 59 (OCR) ===\neuaoue).\n\n=== Page 13 Image 60 (OCR) ===\na\n\n=== Page 13 Image 61 (OCR) ===\n—\n\n=== Page 13 Image 62 (OCR) ===\noe\n\n=== Page 13 Image 63 (OCR) ===\na\n\n=== Page 13 Image 64 (OCR) ===\nQunoue).\n\n=== Page 13 Image 66 (OCR) ===\nguaoue)\n\n=== Page 13 Image 67 (OCR) ===\na\n\n=== Page 13 Image 68 (OCR) ===\nuaoue).\n\n=== Page 13 Image 69 (OCR) ===\neuaoue).\n\n=== Page 13 Image 70 (OCR) ===\na\n\n=== Page 14 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nHigh level assessment of potential strategic options for Oxycontin\n1 Only include Commercial and Part D accounts\n2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza losing 60-70%% of the market share due to exclusion\n2 Assuming decline of branded Oxycodone ER at -1% YoY, and Xtampza share grow by 10-40% YoY\n3 Assuming  Oxycontin share drops by 65%  in 2020  and by 30% YoY in 2021 and 2022 due to exclusion, and Xtampza captures 75% of the share drop from Oxycontin\nKey assumptions, 2022\n3 year financial projection of net sales1 (after rebates and other GtN \nreductions)\nMaintaining current access status could offer highest cumulative net \nsales in the longer term \n13\n%2 \n2%4\n10\n%3\nOxycontin \nShare\nOxycontin \nrebate\nCommercial: \n50%\nMedicare: \n70%\n0%\nCommercial: \n45%\nMedicare: \n69%\n(assuming \n2% increase \nYoY)\nOxycontin net sales1 ($M) \nXtampza net sales1 ($M)\n273\n227\n202\n702\nSecure \nexclusive \nposition \nacross all \ncontracted \naccounts \nMaintain \ncurrent \naccess \nstatus with \nincreasing \nrebates\nPull away \nrebates \nfrom all \naccounts\nxx\n3 year \ntotal\n297\n240\n206\n270\n179\n128\n2020\n21\n2022\n743\n577\n14\n19\n34\n44\n55\n47\n66\n65\n69\n120\n115\n113\n21\n2020\n2022\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 14 Image 1 (OCR) ===\n—\n\n=== Page 14 Image 2 (OCR) ===\noe\n\n=== Page 14 Image 3 (OCR) ===\na\n\n=== Page 14 Image 4 (OCR) ===\nQunoue).\n\n=== Page 14 Image 6 (OCR) ===\nguaoue)\n\n=== Page 14 Image 7 (OCR) ===\na\n\n=== Page 14 Image 8 (OCR) ===\nuaoue).\n\n=== Page 14 Image 9 (OCR) ===\neuaoue).\n\n=== Page 14 Image 10 (OCR) ===\na\n\n=== Page 14 Image 11 (OCR) ===\n—\n\n=== Page 14 Image 12 (OCR) ===\noe\n\n=== Page 14 Image 13 (OCR) ===\na\n\n=== Page 14 Image 14 (OCR) ===\nQunoue).\n\n=== Page 14 Image 16 (OCR) ===\nguaoue)\n\n=== Page 14 Image 17 (OCR) ===\na\n\n=== Page 14 Image 18 (OCR) ===\nuaoue).\n\n=== Page 14 Image 19 (OCR) ===\neuaoue).\n\n=== Page 14 Image 20 (OCR) ===\na\n\n=== Page 14 Image 21 (OCR) ===\n—\n\n=== Page 14 Image 22 (OCR) ===\noe\n\n=== Page 14 Image 23 (OCR) ===\na\n\n=== Page 14 Image 24 (OCR) ===\nQunoue).\n\n=== Page 14 Image 26 (OCR) ===\nguaoue)\n\n=== Page 14 Image 27 (OCR) ===\na\n\n=== Page 14 Image 28 (OCR) ===\nuaoue).\n\n=== Page 14 Image 29 (OCR) ===\neuaoue).\n\n=== Page 14 Image 30 (OCR) ===\na\n\n=== Page 14 Image 31 (OCR) ===\n—\n\n=== Page 14 Image 32 (OCR) ===\noe\n\n=== Page 14 Image 33 (OCR) ===\na\n\n=== Page 14 Image 34 (OCR) ===\nQunoue).\n\n=== Page 14 Image 36 (OCR) ===\nguaoue)\n\n=== Page 14 Image 37 (OCR) ===\na\n\n=== Page 14 Image 38 (OCR) ===\nuaoue).\n\n=== Page 14 Image 39 (OCR) ===\neuaoue).\n\n=== Page 14 Image 40 (OCR) ===\na\n\n=== Page 14 Image 41 (OCR) ===\n—\n\n=== Page 14 Image 42 (OCR) ===\noe\n\n=== Page 14 Image 43 (OCR) ===\na\n\n=== Page 14 Image 44 (OCR) ===\nQunoue).\n\n=== Page 14 Image 46 (OCR) ===\nguaoue)\n\n=== Page 14 Image 47 (OCR) ===\na\n\n=== Page 14 Image 48 (OCR) ===\nuaoue).\n\n=== Page 14 Image 49 (OCR) ===\neuaoue).\n\n=== Page 14 Image 50 (OCR) ===\na\n\n=== Page 14 Image 51 (OCR) ===\n—\n\n=== Page 14 Image 52 (OCR) ===\noe\n\n=== Page 14 Image 53 (OCR) ===\na\n\n=== Page 14 Image 54 (OCR) ===\nQunoue).\n\n=== Page 14 Image 56 (OCR) ===\nguaoue)\n\n=== Page 14 Image 57 (OCR) ===\na\n\n=== Page 14 Image 58 (OCR) ===\nuaoue).\n\n=== Page 14 Image 59 (OCR) ===\neuaoue).\n\n=== Page 14 Image 60 (OCR) ===\na\n\n=== Page 14 Image 61 (OCR) ===\n—\n\n=== Page 14 Image 62 (OCR) ===\noe\n\n=== Page 14 Image 63 (OCR) ===\na\n\n=== Page 14 Image 64 (OCR) ===\nQunoue).\n\n=== Page 14 Image 66 (OCR) ===\nguaoue)\n\n=== Page 14 Image 67 (OCR) ===\na\n\n=== Page 14 Image 68 (OCR) ===\nuaoue).\n\n=== Page 14 Image 69 (OCR) ===\neuaoue).\n\n=== Page 14 Image 70 (OCR) ===\na\n\n=== Page 15 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\n• OxyContin and Hysingla ER maintain strong access on Envision’s formularies, with OxyContin maintaining preferred status on 66% o\nlives \n• Collegium’s products are nearly completely excluded on all Envision formularies\n1 Defined as percentage of lives that are either preferred or covered (including PA/ST)\nCurrent access status: OxyContin is preferred for 66% of lives on Envision Part D formularies\nSOURCE: MMIT\n25\n466\n203\n27\n51\nNot \nCovered\nPreferre\nd\nCovered \n(PA/ST)\nNot \nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST)\nPreferre\nd\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nPrivileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal \nand regulatory review before they can be considered final. These materials are confidential and proprietary.\nMCS Classicare II\nHealthSun MediMax \nPreferre\nd\nNot \nCovered\nPreferre\nd\nNot \nCovered\nEnvisionRxPlus PDP\nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST)\n74%\n1%\n92%\n0%\n65%\nEnvisionRxPlus Hybrid PDP\nHealthTeam Advantage Plan\nCovered \n(PA/ST)\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nLives, K\nOverall formulary \nstatus\nLives, \n%\nHysingl\na ER\nXtampz\na ER\nOxyCo\nntin\nNucynt\na ER\nZohydr\no ER\nLargest formulary\nPurdue \npreferred, \nZohydro covered\nOnly Oxycontin \ncovered\nPurdue portfolio \nexclusive \ncoverage \nOnly branded \nhydrocodone \ncoverage\nOnly Hysingla ER \ncovered\nOverall covered \nlives %1\n59\n%\n26\n%\n7%\n3%\n3%\nOxycontin Covered\nNot cov\nCoverage status of leading ERO brands, \nNov 2018\nENVISION\n789\nTotal\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 15 Image 1 (OCR) ===\n—\n\n=== Page 15 Image 2 (OCR) ===\noe\n\n=== Page 15 Image 3 (OCR) ===\na\n\n=== Page 15 Image 4 (OCR) ===\nQunoue).\n\n=== Page 15 Image 6 (OCR) ===\nguaoue)\n\n=== Page 15 Image 7 (OCR) ===\na\n\n=== Page 15 Image 8 (OCR) ===\nuaoue).\n\n=== Page 15 Image 9 (OCR) ===\neuaoue).\n\n=== Page 15 Image 10 (OCR) ===\na\n\n=== Page 15 Image 11 (OCR) ===\n—\n\n=== Page 15 Image 12 (OCR) ===\noe\n\n=== Page 15 Image 13 (OCR) ===\na\n\n=== Page 15 Image 14 (OCR) ===\nQunoue).\n\n=== Page 15 Image 16 (OCR) ===\nguaoue)\n\n=== Page 15 Image 17 (OCR) ===\na\n\n=== Page 15 Image 18 (OCR) ===\nuaoue).\n\n=== Page 15 Image 19 (OCR) ===\neuaoue).\n\n=== Page 15 Image 20 (OCR) ===\na\n\n=== Page 15 Image 21 (OCR) ===\n—\n\n=== Page 15 Image 22 (OCR) ===\noe\n\n=== Page 15 Image 23 (OCR) ===\na\n\n=== Page 15 Image 24 (OCR) ===\nQunoue).\n\n=== Page 15 Image 26 (OCR) ===\nguaoue)\n\n=== Page 15 Image 27 (OCR) ===\na\n\n=== Page 15 Image 28 (OCR) ===\nuaoue).\n\n=== Page 15 Image 29 (OCR) ===\neuaoue).\n\n=== Page 15 Image 30 (OCR) ===\na\n\n=== Page 15 Image 31 (OCR) ===\n—\n\n=== Page 15 Image 32 (OCR) ===\noe\n\n=== Page 15 Image 33 (OCR) ===\na\n\n=== Page 15 Image 34 (OCR) ===\nQunoue).\n\n=== Page 15 Image 36 (OCR) ===\nguaoue)\n\n=== Page 15 Image 37 (OCR) ===\na\n\n=== Page 15 Image 38 (OCR) ===\nuaoue).\n\n=== Page 15 Image 39 (OCR) ===\neuaoue).\n\n=== Page 15 Image 40 (OCR) ===\na\n\n=== Page 15 Image 41 (OCR) ===\n—\n\n=== Page 15 Image 42 (OCR) ===\noe\n\n=== Page 15 Image 43 (OCR) ===\na\n\n=== Page 15 Image 44 (OCR) ===\nQunoue).\n\n=== Page 15 Image 46 (OCR) ===\nguaoue)\n\n=== Page 15 Image 47 (OCR) ===\na\n\n=== Page 15 Image 48 (OCR) ===\nuaoue).\n\n=== Page 15 Image 49 (OCR) ===\neuaoue).\n\n=== Page 15 Image 50 (OCR) ===\na\n\n=== Page 15 Image 51 (OCR) ===\n—\n\n=== Page 15 Image 52 (OCR) ===\noe\n\n=== Page 15 Image 53 (OCR) ===\na\n\n=== Page 15 Image 54 (OCR) ===\nQunoue).\n\n=== Page 15 Image 56 (OCR) ===\nguaoue)\n\n=== Page 15 Image 57 (OCR) ===\na\n\n=== Page 15 Image 58 (OCR) ===\nuaoue).\n\n=== Page 15 Image 59 (OCR) ===\neuaoue).\n\n=== Page 15 Image 60 (OCR) ===\na\n\n=== Page 15 Image 61 (OCR) ===\n—\n\n=== Page 15 Image 62 (OCR) ===\noe\n\n=== Page 15 Image 63 (OCR) ===\na\n\n=== Page 15 Image 64 (OCR) ===\nQunoue).\n\n=== Page 15 Image 66 (OCR) ===\nguaoue)\n\n=== Page 15 Image 67 (OCR) ===\na\n\n=== Page 15 Image 68 (OCR) ===\nuaoue).\n\n=== Page 15 Image 69 (OCR) ===\neuaoue).\n\n=== Page 15 Image 70 (OCR) ===\na\n\n=== Page 16 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe defined potential 2020 access scenarios for Oxycontin vs. Xtampza\n2020 Share shift assumptions under different scenarios, 2020 Q4 \n2020 access \nscenarios\nContinue current \naccess status as  \nexclusive preferred \noxycodone ER\n1\nBoth Oxycontin and \nXtampza preferred \n2\nXtampza preferred, \nOxycontin non-\npreferred\n3\nXtampza replaces \nOxycontin as \nexclusive preferred \nwith \ngrandfathering\n4\nOxycontin Excluded \nwithout \ngrandfathering\n5\n5\n1\n6\n15\n8\n7\n8\n3\n12\n9\n5\n4\n11\n8\n9\n6\n8\n6\n9\n8\n9\n7\n6\n9\n3\n10\n7\nOxycontin\nXtampza\nOther \nShare by products (exit share) \nShare shift vs. \nstatus quo \nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\n20%\n40%\n30%\n68%\n50%\n70%\n60%\n80%\n0%\nPRIME\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 16 Image 1 (OCR) ===\n—\n\n=== Page 16 Image 2 (OCR) ===\noe\n\n=== Page 16 Image 3 (OCR) ===\na\n\n=== Page 16 Image 4 (OCR) ===\nQunoue).\n\n=== Page 16 Image 6 (OCR) ===\nguaoue)\n\n=== Page 16 Image 7 (OCR) ===\na\n\n=== Page 16 Image 8 (OCR) ===\nuaoue).\n\n=== Page 16 Image 9 (OCR) ===\neuaoue).\n\n=== Page 16 Image 10 (OCR) ===\na\n\n=== Page 16 Image 11 (OCR) ===\n—\n\n=== Page 16 Image 12 (OCR) ===\noe\n\n=== Page 16 Image 13 (OCR) ===\na\n\n=== Page 16 Image 14 (OCR) ===\nQunoue).\n\n=== Page 16 Image 16 (OCR) ===\nguaoue)\n\n=== Page 16 Image 17 (OCR) ===\na\n\n=== Page 16 Image 18 (OCR) ===\nuaoue).\n\n=== Page 16 Image 19 (OCR) ===\neuaoue).\n\n=== Page 16 Image 20 (OCR) ===\na\n\n=== Page 16 Image 21 (OCR) ===\n—\n\n=== Page 16 Image 22 (OCR) ===\noe\n\n=== Page 16 Image 23 (OCR) ===\na\n\n=== Page 16 Image 24 (OCR) ===\nQunoue).\n\n=== Page 16 Image 26 (OCR) ===\nguaoue)\n\n=== Page 16 Image 27 (OCR) ===\na\n\n=== Page 16 Image 28 (OCR) ===\nuaoue).\n\n=== Page 16 Image 29 (OCR) ===\neuaoue).\n\n=== Page 16 Image 30 (OCR) ===\na\n\n=== Page 16 Image 31 (OCR) ===\n—\n\n=== Page 16 Image 32 (OCR) ===\noe\n\n=== Page 16 Image 33 (OCR) ===\na\n\n=== Page 16 Image 34 (OCR) ===\nQunoue).\n\n=== Page 16 Image 36 (OCR) ===\nguaoue)\n\n=== Page 16 Image 37 (OCR) ===\na\n\n=== Page 16 Image 38 (OCR) ===\nuaoue).\n\n=== Page 16 Image 39 (OCR) ===\neuaoue).\n\n=== Page 16 Image 40 (OCR) ===\na\n\n=== Page 16 Image 41 (OCR) ===\n—\n\n=== Page 16 Image 42 (OCR) ===\noe\n\n=== Page 16 Image 43 (OCR) ===\na\n\n=== Page 16 Image 44 (OCR) ===\nQunoue).\n\n=== Page 16 Image 46 (OCR) ===\nguaoue)\n\n=== Page 16 Image 47 (OCR) ===\na\n\n=== Page 16 Image 48 (OCR) ===\nuaoue).\n\n=== Page 16 Image 49 (OCR) ===\neuaoue).\n\n=== Page 16 Image 50 (OCR) ===\na\n\n=== Page 16 Image 51 (OCR) ===\n—\n\n=== Page 16 Image 52 (OCR) ===\noe\n\n=== Page 16 Image 53 (OCR) ===\na\n\n=== Page 16 Image 54 (OCR) ===\nQunoue).\n\n=== Page 16 Image 56 (OCR) ===\nguaoue)\n\n=== Page 16 Image 57 (OCR) ===\na\n\n=== Page 16 Image 58 (OCR) ===\nuaoue).\n\n=== Page 16 Image 59 (OCR) ===\neuaoue).\n\n=== Page 16 Image 60 (OCR) ===\na\n\n=== Page 16 Image 61 (OCR) ===\n—\n\n=== Page 16 Image 62 (OCR) ===\noe\n\n=== Page 16 Image 63 (OCR) ===\na\n\n=== Page 16 Image 64 (OCR) ===\nQunoue).\n\n=== Page 16 Image 66 (OCR) ===\nguaoue)\n\n=== Page 16 Image 67 (OCR) ===\na\n\n=== Page 16 Image 68 (OCR) ===\nuaoue).\n\n=== Page 16 Image 69 (OCR) ===\neuaoue).\n\n=== Page 16 Image 70 (OCR) ===\na\n\n=== Page 17 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n10.8\n11.0\n11.5\n13.2\n7.2\n6.2\n11.2\n7.9\n10.2\n6.6\n2020 access \nscenarios\nBoth \nOxycontin and \nXtampza \npreferred \nXtampza \npreferred, \nOxycontin \nnon-preferred\nContinue \ncurrent access \nstatus as  \nexclusive \npreferred\noxycodone ER\nXtampza \nreplacing \nOxycontin as \nexclusive \npreferred with \ngrandfathering\nOxycontin \nExcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n4\n0%\n40%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\n to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. \n2.1\n3.2\n0.8\n2.9\n1.6\n1.1\n1.8\n1.6\nShare by \nproduct, 2020 \nQ4\nOther brand \nnet sales ($M)\n5\n3\n22\n9\n8\n7\n12\n22\n6\n4\n5\n9\n6\n8\n11\n9\n7\n6\n8\n22\n8\n5\n9\n8\n9\n7\n10\n3\n22\n22\n22\n22\n22\n8.0\n7.3\n7.7\n8.8\n8.4\n8.8\n9.2\n9.6\nOxycontin\nOther brands\nXtampza\nPRIME\n0.7\n22\n6\n1\n15\n6.5\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nShar\ne \nshift\nBreak-\neven \nrebate2 \n37%\n48%\n32%\n37%\nN/A\n30%\n44%\n60%\n45%\nNet sales at min \nrebate ($M)\n42%\nRebate rate to keep \nPrime whole1 \n30%\n44%\n27%\n40%\nN/A\n24%\n36%\n32%\nTheoretic\nal – \nunlikely \nable to \nlower \ncurrent \nrate \n(40%)\n4\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 17 Image 1 (OCR) ===\n—\n\n=== Page 17 Image 2 (OCR) ===\noe\n\n=== Page 17 Image 3 (OCR) ===\na\n\n=== Page 17 Image 4 (OCR) ===\nQunoue).\n\n=== Page 17 Image 6 (OCR) ===\nguaoue)\n\n=== Page 17 Image 7 (OCR) ===\na\n\n=== Page 17 Image 8 (OCR) ===\nuaoue).\n\n=== Page 17 Image 9 (OCR) ===\neuaoue).\n\n=== Page 17 Image 10 (OCR) ===\na\n\n=== Page 17 Image 11 (OCR) ===\n—\n\n=== Page 17 Image 12 (OCR) ===\noe\n\n=== Page 17 Image 13 (OCR) ===\na\n\n=== Page 17 Image 14 (OCR) ===\nQunoue).\n\n=== Page 17 Image 16 (OCR) ===\nguaoue)\n\n=== Page 17 Image 17 (OCR) ===\na\n\n=== Page 17 Image 18 (OCR) ===\nuaoue).\n\n=== Page 17 Image 19 (OCR) ===\neuaoue).\n\n=== Page 17 Image 20 (OCR) ===\na\n\n=== Page 17 Image 21 (OCR) ===\n—\n\n=== Page 17 Image 22 (OCR) ===\noe\n\n=== Page 17 Image 23 (OCR) ===\na\n\n=== Page 17 Image 24 (OCR) ===\nQunoue).\n\n=== Page 17 Image 26 (OCR) ===\nguaoue)\n\n=== Page 17 Image 27 (OCR) ===\na\n\n=== Page 17 Image 28 (OCR) ===\nuaoue).\n\n=== Page 17 Image 29 (OCR) ===\neuaoue).\n\n=== Page 17 Image 30 (OCR) ===\na\n\n=== Page 17 Image 31 (OCR) ===\n—\n\n=== Page 17 Image 32 (OCR) ===\noe\n\n=== Page 17 Image 33 (OCR) ===\na\n\n=== Page 17 Image 34 (OCR) ===\nQunoue).\n\n=== Page 17 Image 36 (OCR) ===\nguaoue)\n\n=== Page 17 Image 37 (OCR) ===\na\n\n=== Page 17 Image 38 (OCR) ===\nuaoue).\n\n=== Page 17 Image 39 (OCR) ===\neuaoue).\n\n=== Page 17 Image 40 (OCR) ===\na\n\n=== Page 17 Image 41 (OCR) ===\n—\n\n=== Page 17 Image 42 (OCR) ===\noe\n\n=== Page 17 Image 43 (OCR) ===\na\n\n=== Page 17 Image 44 (OCR) ===\nQunoue).\n\n=== Page 17 Image 46 (OCR) ===\nguaoue)\n\n=== Page 17 Image 47 (OCR) ===\na\n\n=== Page 17 Image 48 (OCR) ===\nuaoue).\n\n=== Page 17 Image 49 (OCR) ===\neuaoue).\n\n=== Page 17 Image 50 (OCR) ===\na\n\n=== Page 17 Image 51 (OCR) ===\n—\n\n=== Page 17 Image 52 (OCR) ===\noe\n\n=== Page 17 Image 53 (OCR) ===\na\n\n=== Page 17 Image 54 (OCR) ===\nQunoue).\n\n=== Page 17 Image 56 (OCR) ===\nguaoue)\n\n=== Page 17 Image 57 (OCR) ===\na\n\n=== Page 17 Image 58 (OCR) ===\nuaoue).\n\n=== Page 17 Image 59 (OCR) ===\neuaoue).\n\n=== Page 17 Image 60 (OCR) ===\na\n\n=== Page 17 Image 61 (OCR) ===\n—\n\n=== Page 17 Image 62 (OCR) ===\noe\n\n=== Page 17 Image 63 (OCR) ===\na\n\n=== Page 17 Image 64 (OCR) ===\nQunoue).\n\n=== Page 17 Image 66 (OCR) ===\nguaoue)\n\n=== Page 17 Image 67 (OCR) ===\na\n\n=== Page 17 Image 68 (OCR) ===\nuaoue).\n\n=== Page 17 Image 69 (OCR) ===\neuaoue).\n\n=== Page 17 Image 70 (OCR) ===\na\n\n=== Page 18 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nLong term view: 2020-2022 financial impact under different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering  \n20.3\n17.3\n10.2\n14.5\n16.0\n19.4\n12.5\n19.2\nAccess scenarios\nBoth Oxycontin \nand Xtampza \npreferred \nXtampza \npreferred, \nOxycontin non-\npreferred\nContinue current \naccess status as  \nexclusive preferred\noxycodone ER\nXtampza replacing \nOxycontin as \nexclusive preferred \nwith grandfathering\n60%\n50%\n43%\n5%\n0%\nOxycontin \nExcluded without \ngrandfathering\n2020\n1\n2\n3\n4\nAssumed \nOxycontin \nrebate, 2022\n3 year total ($M)\nShare \nshift\nMaintaining  current access status could maximize net sales in the longer term as well, assuming reasonable increase in rebate rate\n6.6\n10.6\n9.6\n8.7\n10.2\n7.5\n10.6\n11.1\nShare by \nproduct, 2022 \nQ4\n2021\n5\n20\n3\n5\n20\n4\n8\n20\n9\n7\n10\n7\n8\n8\n5\n9\n7\n9\n9\n9\n2\n9\n20\n10\n20\n1\n20\n9\n1\n9\n1\n20\n20\n3.4\n6.0\n2.6\n5.6\n6.4\n4.8\n3.4\n5.1\nOxycontin\nOther brands\nXtampza\nPRIME\n10.8\n0 6\n13\n20\n7.3\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nLow\nHigh\nOxycontin net sales ($M)\n2022\n4.3\n2.8\n3.3\n1.5\n2.5\n1.6\n2.4\n1.0\n2.0\n22.4\n5\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 18 Image 1 (OCR) ===\n—\n\n=== Page 18 Image 2 (OCR) ===\noe\n\n=== Page 18 Image 3 (OCR) ===\na\n\n=== Page 18 Image 4 (OCR) ===\nQunoue).\n\n=== Page 18 Image 6 (OCR) ===\nguaoue)\n\n=== Page 18 Image 7 (OCR) ===\na\n\n=== Page 18 Image 8 (OCR) ===\nuaoue).\n\n=== Page 18 Image 9 (OCR) ===\neuaoue).\n\n=== Page 18 Image 10 (OCR) ===\na\n\n=== Page 18 Image 11 (OCR) ===\n—\n\n=== Page 18 Image 12 (OCR) ===\noe\n\n=== Page 18 Image 13 (OCR) ===\na\n\n=== Page 18 Image 14 (OCR) ===\nQunoue).\n\n=== Page 18 Image 16 (OCR) ===\nguaoue)\n\n=== Page 18 Image 17 (OCR) ===\na\n\n=== Page 18 Image 18 (OCR) ===\nuaoue).\n\n=== Page 18 Image 19 (OCR) ===\neuaoue).\n\n=== Page 18 Image 20 (OCR) ===\na\n\n=== Page 18 Image 21 (OCR) ===\n—\n\n=== Page 18 Image 22 (OCR) ===\noe\n\n=== Page 18 Image 23 (OCR) ===\na\n\n=== Page 18 Image 24 (OCR) ===\nQunoue).\n\n=== Page 18 Image 26 (OCR) ===\nguaoue)\n\n=== Page 18 Image 27 (OCR) ===\na\n\n=== Page 18 Image 28 (OCR) ===\nuaoue).\n\n=== Page 18 Image 29 (OCR) ===\neuaoue).\n\n=== Page 18 Image 30 (OCR) ===\na\n\n=== Page 18 Image 31 (OCR) ===\n—\n\n=== Page 18 Image 32 (OCR) ===\noe\n\n=== Page 18 Image 33 (OCR) ===\na\n\n=== Page 18 Image 34 (OCR) ===\nQunoue).\n\n=== Page 18 Image 36 (OCR) ===\nguaoue)\n\n=== Page 18 Image 37 (OCR) ===\na\n\n=== Page 18 Image 38 (OCR) ===\nuaoue).\n\n=== Page 18 Image 39 (OCR) ===\neuaoue).\n\n=== Page 18 Image 40 (OCR) ===\na\n\n=== Page 18 Image 41 (OCR) ===\n—\n\n=== Page 18 Image 42 (OCR) ===\noe\n\n=== Page 18 Image 43 (OCR) ===\na\n\n=== Page 18 Image 44 (OCR) ===\nQunoue).\n\n=== Page 18 Image 46 (OCR) ===\nguaoue)\n\n=== Page 18 Image 47 (OCR) ===\na\n\n=== Page 18 Image 48 (OCR) ===\nuaoue).\n\n=== Page 18 Image 49 (OCR) ===\neuaoue).\n\n=== Page 18 Image 50 (OCR) ===\na\n\n=== Page 18 Image 51 (OCR) ===\n—\n\n=== Page 18 Image 52 (OCR) ===\noe\n\n=== Page 18 Image 53 (OCR) ===\na\n\n=== Page 18 Image 54 (OCR) ===\nQunoue).\n\n=== Page 18 Image 56 (OCR) ===\nguaoue)\n\n=== Page 18 Image 57 (OCR) ===\na\n\n=== Page 18 Image 58 (OCR) ===\nuaoue).\n\n=== Page 18 Image 59 (OCR) ===\neuaoue).\n\n=== Page 18 Image 60 (OCR) ===\na\n\n=== Page 18 Image 61 (OCR) ===\n—\n\n=== Page 18 Image 62 (OCR) ===\noe\n\n=== Page 18 Image 63 (OCR) ===\na\n\n=== Page 18 Image 64 (OCR) ===\nQunoue).\n\n=== Page 18 Image 66 (OCR) ===\nguaoue)\n\n=== Page 18 Image 67 (OCR) ===\na\n\n=== Page 18 Image 68 (OCR) ===\nuaoue).\n\n=== Page 18 Image 69 (OCR) ===\neuaoue).\n\n=== Page 18 Image 70 (OCR) ===\na\n\n=== Page 19 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nBACKUP\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 19 Image 1 (OCR) ===\n—\n\n=== Page 19 Image 2 (OCR) ===\noe\n\n=== Page 19 Image 3 (OCR) ===\na\n\n=== Page 19 Image 4 (OCR) ===\nQunoue).\n\n=== Page 19 Image 6 (OCR) ===\nguaoue)\n\n=== Page 19 Image 7 (OCR) ===\na\n\n=== Page 19 Image 8 (OCR) ===\nuaoue).\n\n=== Page 19 Image 9 (OCR) ===\neuaoue).\n\n=== Page 19 Image 10 (OCR) ===\na\n\n=== Page 19 Image 11 (OCR) ===\n—\n\n=== Page 19 Image 12 (OCR) ===\noe\n\n=== Page 19 Image 13 (OCR) ===\na\n\n=== Page 19 Image 14 (OCR) ===\nQunoue).\n\n=== Page 19 Image 16 (OCR) ===\nguaoue)\n\n=== Page 19 Image 17 (OCR) ===\na\n\n=== Page 19 Image 18 (OCR) ===\nuaoue).\n\n=== Page 19 Image 19 (OCR) ===\neuaoue).\n\n=== Page 19 Image 20 (OCR) ===\na\n\n=== Page 19 Image 21 (OCR) ===\n—\n\n=== Page 19 Image 22 (OCR) ===\noe\n\n=== Page 19 Image 23 (OCR) ===\na\n\n=== Page 19 Image 24 (OCR) ===\nQunoue).\n\n=== Page 19 Image 26 (OCR) ===\nguaoue)\n\n=== Page 19 Image 27 (OCR) ===\na\n\n=== Page 19 Image 28 (OCR) ===\nuaoue).\n\n=== Page 19 Image 29 (OCR) ===\neuaoue).\n\n=== Page 19 Image 30 (OCR) ===\na\n\n=== Page 19 Image 31 (OCR) ===\n—\n\n=== Page 19 Image 32 (OCR) ===\noe\n\n=== Page 19 Image 33 (OCR) ===\na\n\n=== Page 19 Image 34 (OCR) ===\nQunoue).\n\n=== Page 19 Image 36 (OCR) ===\nguaoue)\n\n=== Page 19 Image 37 (OCR) ===\na\n\n=== Page 19 Image 38 (OCR) ===\nuaoue).\n\n=== Page 19 Image 39 (OCR) ===\neuaoue).\n\n=== Page 19 Image 40 (OCR) ===\na\n\n=== Page 19 Image 41 (OCR) ===\n—\n\n=== Page 19 Image 42 (OCR) ===\noe\n\n=== Page 19 Image 43 (OCR) ===\na\n\n=== Page 19 Image 44 (OCR) ===\nQunoue).\n\n=== Page 19 Image 46 (OCR) ===\nguaoue)\n\n=== Page 19 Image 47 (OCR) ===\na\n\n=== Page 19 Image 48 (OCR) ===\nuaoue).\n\n=== Page 19 Image 49 (OCR) ===\neuaoue).\n\n=== Page 19 Image 50 (OCR) ===\na\n\n=== Page 19 Image 51 (OCR) ===\n—\n\n=== Page 19 Image 52 (OCR) ===\noe\n\n=== Page 19 Image 53 (OCR) ===\na\n\n=== Page 19 Image 54 (OCR) ===\nQunoue).\n\n=== Page 19 Image 56 (OCR) ===\nguaoue)\n\n=== Page 19 Image 57 (OCR) ===\na\n\n=== Page 19 Image 58 (OCR) ===\nuaoue).\n\n=== Page 19 Image 59 (OCR) ===\neuaoue).\n\n=== Page 19 Image 60 (OCR) ===\na\n\n=== Page 19 Image 61 (OCR) ===\n—\n\n=== Page 19 Image 62 (OCR) ===\noe\n\n=== Page 19 Image 63 (OCR) ===\na\n\n=== Page 19 Image 64 (OCR) ===\nQunoue).\n\n=== Page 19 Image 66 (OCR) ===\nguaoue)\n\n=== Page 19 Image 67 (OCR) ===\na\n\n=== Page 19 Image 68 (OCR) ===\nuaoue).\n\n=== Page 19 Image 69 (OCR) ===\neuaoue).\n\n=== Page 19 Image 70 (OCR) ===\na\n\n=== Page 20 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nAssessment of current performance of Collegium\nCollegium strategy going forward: key ingoing assumptions\n• 2 product portfolio exclusively in pain management therapeutic area, with \nR&D pipeline all early life (Ph II or earlier) and concentrated in pain \nmanagement1\n• Facing “finite” market for its current portfolio, driven by:\n– Overall U.S. ERO market continuing to decline (-15% YoY decline2 until \n2020)\n– Likely genericization of extended-release oxycodone with abuse-deterrent \nformulations, leading to a market shift away from branded opioids\n• Product portfolio is facing challenges\n– Xtampza ER (oxycodone): $50.9M sales in Q1-Q3 20182\n• Competing with an established market leader in a highly genericized class\n– Nucynta (tapentadol): $156M sales in Q1-Q3 20182\n• Slow launch since acquisition and experiencing share loss (-4% TRx from \nQ2-Q3 ’18)\n• Collegium responsible for minimum $135M/yr royalty payment for first 4 \nyears of licensing regardless of product performance\n• Collegium continues to invest in salesforce reps (~150) calling on specialists \n(~10,700) for both products\n• Overall, Collegium is unprofitable ($31M loss from operations Q1-Q3 2018)\n– ($0.50) EPS for Q3 ’18, missing Thomson Reuters’ consensus estimate of \n($0 36)\n1 Collegium has one preclinical ADHD molecule\n2 Based on Purdue internal projection\n3 Based on Collegium 2018 Q3 10-Q \n• Given finite market \noutlook and Collegium’s \nneed to quickly return to \nprofitability, there are 2 \npotential strategic \nchoices:\n– Reduce cost by \ndownsizing salesforces, \nwhich could potentially \nlower expected sales \ngrowth\n– Augment volume with \naggressive bidding \nSOURCE: SEC filings, Internal research\n-27 sales from PD “Perspective on global \nopioid and opiate markets” for narcotic \nproducts; \n7\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 20 Image 1 (OCR) ===\n—\n\n=== Page 20 Image 2 (OCR) ===\noe\n\n=== Page 20 Image 3 (OCR) ===\na\n\n=== Page 20 Image 4 (OCR) ===\nQunoue).\n\n=== Page 20 Image 6 (OCR) ===\nguaoue)\n\n=== Page 20 Image 7 (OCR) ===\na\n\n=== Page 20 Image 8 (OCR) ===\nuaoue).\n\n=== Page 20 Image 9 (OCR) ===\neuaoue).\n\n=== Page 20 Image 10 (OCR) ===\na\n\n=== Page 20 Image 11 (OCR) ===\n—\n\n=== Page 20 Image 12 (OCR) ===\noe\n\n=== Page 20 Image 13 (OCR) ===\na\n\n=== Page 20 Image 14 (OCR) ===\nQunoue).\n\n=== Page 20 Image 16 (OCR) ===\nguaoue)\n\n=== Page 20 Image 17 (OCR) ===\na\n\n=== Page 20 Image 18 (OCR) ===\nuaoue).\n\n=== Page 20 Image 19 (OCR) ===\neuaoue).\n\n=== Page 20 Image 20 (OCR) ===\na\n\n=== Page 20 Image 21 (OCR) ===\n—\n\n=== Page 20 Image 22 (OCR) ===\noe\n\n=== Page 20 Image 23 (OCR) ===\na\n\n=== Page 20 Image 24 (OCR) ===\nQunoue).\n\n=== Page 20 Image 26 (OCR) ===\nguaoue)\n\n=== Page 20 Image 27 (OCR) ===\na\n\n=== Page 20 Image 28 (OCR) ===\nuaoue).\n\n=== Page 20 Image 29 (OCR) ===\neuaoue).\n\n=== Page 20 Image 30 (OCR) ===\na\n\n=== Page 20 Image 31 (OCR) ===\n—\n\n=== Page 20 Image 32 (OCR) ===\noe\n\n=== Page 20 Image 33 (OCR) ===\na\n\n=== Page 20 Image 34 (OCR) ===\nQunoue).\n\n=== Page 20 Image 36 (OCR) ===\nguaoue)\n\n=== Page 20 Image 37 (OCR) ===\na\n\n=== Page 20 Image 38 (OCR) ===\nuaoue).\n\n=== Page 20 Image 39 (OCR) ===\neuaoue).\n\n=== Page 20 Image 40 (OCR) ===\na\n\n=== Page 20 Image 41 (OCR) ===\n—\n\n=== Page 20 Image 42 (OCR) ===\noe\n\n=== Page 20 Image 43 (OCR) ===\na\n\n=== Page 20 Image 44 (OCR) ===\nQunoue).\n\n=== Page 20 Image 46 (OCR) ===\nguaoue)\n\n=== Page 20 Image 47 (OCR) ===\na\n\n=== Page 20 Image 48 (OCR) ===\nuaoue).\n\n=== Page 20 Image 49 (OCR) ===\neuaoue).\n\n=== Page 20 Image 50 (OCR) ===\na\n\n=== Page 20 Image 51 (OCR) ===\n—\n\n=== Page 20 Image 52 (OCR) ===\noe\n\n=== Page 20 Image 53 (OCR) ===\na\n\n=== Page 20 Image 54 (OCR) ===\nQunoue).\n\n=== Page 20 Image 56 (OCR) ===\nguaoue)\n\n=== Page 20 Image 57 (OCR) ===\na\n\n=== Page 20 Image 58 (OCR) ===\nuaoue).\n\n=== Page 20 Image 59 (OCR) ===\neuaoue).\n\n=== Page 20 Image 60 (OCR) ===\na\n\n=== Page 20 Image 61 (OCR) ===\n—\n\n=== Page 20 Image 62 (OCR) ===\noe\n\n=== Page 20 Image 63 (OCR) ===\na\n\n=== Page 20 Image 64 (OCR) ===\nQunoue).\n\n=== Page 20 Image 66 (OCR) ===\nguaoue)\n\n=== Page 20 Image 67 (OCR) ===\na\n\n=== Page 20 Image 68 (OCR) ===\nuaoue).\n\n=== Page 20 Image 69 (OCR) ===\neuaoue).\n\n=== Page 20 Image 70 (OCR) ===\na\n\n=== Page 21 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent view of Collegium profitability\n452\n217\n174\n172\n63\n70\n182\n80\n-32\nGross sales\nLoss \nfrom \noperati\nons\nRebates\nOther \nGTN \nreductio\nns\nNet sales\n9\nCOGS\nR&D\nSG&A\n24\n252\n626\n88\n287\n128\n32\nXtampza\nNucynta\nOverall \nRevenue and GTN \nreductions\nCosts and operating \nexpenses\n2018 financial performance (estimation) \n($ Millions)\n• Cash at the end of \nQ3 2018:  ~$140 \nMn\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 21 Image 1 (OCR) ===\n—\n\n=== Page 21 Image 2 (OCR) ===\noe\n\n=== Page 21 Image 3 (OCR) ===\na\n\n=== Page 21 Image 4 (OCR) ===\nQunoue).\n\n=== Page 21 Image 6 (OCR) ===\nguaoue)\n\n=== Page 21 Image 7 (OCR) ===\na\n\n=== Page 21 Image 8 (OCR) ===\nuaoue).\n\n=== Page 21 Image 9 (OCR) ===\neuaoue).\n\n=== Page 21 Image 10 (OCR) ===\na\n\n=== Page 21 Image 11 (OCR) ===\n—\n\n=== Page 21 Image 12 (OCR) ===\noe\n\n=== Page 21 Image 13 (OCR) ===\na\n\n=== Page 21 Image 14 (OCR) ===\nQunoue).\n\n=== Page 21 Image 16 (OCR) ===\nguaoue)\n\n=== Page 21 Image 17 (OCR) ===\na\n\n=== Page 21 Image 18 (OCR) ===\nuaoue).\n\n=== Page 21 Image 19 (OCR) ===\neuaoue).\n\n=== Page 21 Image 20 (OCR) ===\na\n\n=== Page 21 Image 21 (OCR) ===\n—\n\n=== Page 21 Image 22 (OCR) ===\noe\n\n=== Page 21 Image 23 (OCR) ===\na\n\n=== Page 21 Image 24 (OCR) ===\nQunoue).\n\n=== Page 21 Image 26 (OCR) ===\nguaoue)\n\n=== Page 21 Image 27 (OCR) ===\na\n\n=== Page 21 Image 28 (OCR) ===\nuaoue).\n\n=== Page 21 Image 29 (OCR) ===\neuaoue).\n\n=== Page 21 Image 30 (OCR) ===\na\n\n=== Page 21 Image 31 (OCR) ===\n—\n\n=== Page 21 Image 32 (OCR) ===\noe\n\n=== Page 21 Image 33 (OCR) ===\na\n\n=== Page 21 Image 34 (OCR) ===\nQunoue).\n\n=== Page 21 Image 36 (OCR) ===\nguaoue)\n\n=== Page 21 Image 37 (OCR) ===\na\n\n=== Page 21 Image 38 (OCR) ===\nuaoue).\n\n=== Page 21 Image 39 (OCR) ===\neuaoue).\n\n=== Page 21 Image 40 (OCR) ===\na\n\n=== Page 21 Image 41 (OCR) ===\n—\n\n=== Page 21 Image 42 (OCR) ===\noe\n\n=== Page 21 Image 43 (OCR) ===\na\n\n=== Page 21 Image 44 (OCR) ===\nQunoue).\n\n=== Page 21 Image 46 (OCR) ===\nguaoue)\n\n=== Page 21 Image 47 (OCR) ===\na\n\n=== Page 21 Image 48 (OCR) ===\nuaoue).\n\n=== Page 21 Image 49 (OCR) ===\neuaoue).\n\n=== Page 21 Image 50 (OCR) ===\na\n\n=== Page 21 Image 51 (OCR) ===\n—\n\n=== Page 21 Image 52 (OCR) ===\noe\n\n=== Page 21 Image 53 (OCR) ===\na\n\n=== Page 21 Image 54 (OCR) ===\nQunoue).\n\n=== Page 21 Image 56 (OCR) ===\nguaoue)\n\n=== Page 21 Image 57 (OCR) ===\na\n\n=== Page 21 Image 58 (OCR) ===\nuaoue).\n\n=== Page 21 Image 59 (OCR) ===\neuaoue).\n\n=== Page 21 Image 60 (OCR) ===\na\n\n=== Page 21 Image 61 (OCR) ===\n—\n\n=== Page 21 Image 62 (OCR) ===\noe\n\n=== Page 21 Image 63 (OCR) ===\na\n\n=== Page 21 Image 64 (OCR) ===\nQunoue).\n\n=== Page 21 Image 66 (OCR) ===\nguaoue)\n\n=== Page 21 Image 67 (OCR) ===\na\n\n=== Page 21 Image 68 (OCR) ===\nuaoue).\n\n=== Page 21 Image 69 (OCR) ===\neuaoue).\n\n=== Page 21 Image 70 (OCR) ===\na\n\n=== Page 22 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCollegium would need to double current share of Xtampza in order to break even\n9\nPotential impact of doubling Xtampza share through exclusive contracts with additional payors\n14\nCurrent loss \nfrom \noperations\n2020 \noperating \nincome\nLoss due to \nmarket \ndecline\nGrowth from \nexisting \naccount\nGrowth \nfrom new \naccount\nCOGS increase\n0\n32\n19\n15\n50\nKey \nassumptions:\n• ERO market \ncontinues to \ndecline at -15% \nyear on year \nuntil 2020\n• GtN of sales with \nnew account: \n60%\n• Nucynta sales \nremains the \nsame\n• SG&A remains \nthe same\nProjected 2020 Xtampza  financial performance \n($ Millions)\nDIRECTIONAL ESTIMATION\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 22 Image 1 (OCR) ===\n—\n\n=== Page 22 Image 2 (OCR) ===\noe\n\n=== Page 22 Image 3 (OCR) ===\na\n\n=== Page 22 Image 4 (OCR) ===\nQunoue).\n\n=== Page 22 Image 6 (OCR) ===\nguaoue)\n\n=== Page 22 Image 7 (OCR) ===\na\n\n=== Page 22 Image 8 (OCR) ===\nuaoue).\n\n=== Page 22 Image 9 (OCR) ===\neuaoue).\n\n=== Page 22 Image 10 (OCR) ===\na\n\n=== Page 22 Image 11 (OCR) ===\n—\n\n=== Page 22 Image 12 (OCR) ===\noe\n\n=== Page 22 Image 13 (OCR) ===\na\n\n=== Page 22 Image 14 (OCR) ===\nQunoue).\n\n=== Page 22 Image 16 (OCR) ===\nguaoue)\n\n=== Page 22 Image 17 (OCR) ===\na\n\n=== Page 22 Image 18 (OCR) ===\nuaoue).\n\n=== Page 22 Image 19 (OCR) ===\neuaoue).\n\n=== Page 22 Image 20 (OCR) ===\na\n\n=== Page 22 Image 21 (OCR) ===\n—\n\n=== Page 22 Image 22 (OCR) ===\noe\n\n=== Page 22 Image 23 (OCR) ===\na\n\n=== Page 22 Image 24 (OCR) ===\nQunoue).\n\n=== Page 22 Image 26 (OCR) ===\nguaoue)\n\n=== Page 22 Image 27 (OCR) ===\na\n\n=== Page 22 Image 28 (OCR) ===\nuaoue).\n\n=== Page 22 Image 29 (OCR) ===\neuaoue).\n\n=== Page 22 Image 30 (OCR) ===\na\n\n=== Page 22 Image 31 (OCR) ===\n—\n\n=== Page 22 Image 32 (OCR) ===\noe\n\n=== Page 22 Image 33 (OCR) ===\na\n\n=== Page 22 Image 34 (OCR) ===\nQunoue).\n\n=== Page 22 Image 36 (OCR) ===\nguaoue)\n\n=== Page 22 Image 37 (OCR) ===\na\n\n=== Page 22 Image 38 (OCR) ===\nuaoue).\n\n=== Page 22 Image 39 (OCR) ===\neuaoue).\n\n=== Page 22 Image 40 (OCR) ===\na\n\n=== Page 22 Image 41 (OCR) ===\n—\n\n=== Page 22 Image 42 (OCR) ===\noe\n\n=== Page 22 Image 43 (OCR) ===\na\n\n=== Page 22 Image 44 (OCR) ===\nQunoue).\n\n=== Page 22 Image 46 (OCR) ===\nguaoue)\n\n=== Page 22 Image 47 (OCR) ===\na\n\n=== Page 22 Image 48 (OCR) ===\nuaoue).\n\n=== Page 22 Image 49 (OCR) ===\neuaoue).\n\n=== Page 22 Image 50 (OCR) ===\na\n\n=== Page 22 Image 51 (OCR) ===\n—\n\n=== Page 22 Image 52 (OCR) ===\noe\n\n=== Page 22 Image 53 (OCR) ===\na\n\n=== Page 22 Image 54 (OCR) ===\nQunoue).\n\n=== Page 22 Image 56 (OCR) ===\nguaoue)\n\n=== Page 22 Image 57 (OCR) ===\na\n\n=== Page 22 Image 58 (OCR) ===\nuaoue).\n\n=== Page 22 Image 59 (OCR) ===\neuaoue).\n\n=== Page 22 Image 60 (OCR) ===\na\n\n=== Page 22 Image 61 (OCR) ===\n—\n\n=== Page 22 Image 62 (OCR) ===\noe\n\n=== Page 22 Image 63 (OCR) ===\na\n\n=== Page 22 Image 64 (OCR) ===\nQunoue).\n\n=== Page 22 Image 66 (OCR) ===\nguaoue)\n\n=== Page 22 Image 67 (OCR) ===\na\n\n=== Page 22 Image 68 (OCR) ===\nuaoue).\n\n=== Page 22 Image 69 (OCR) ===\neuaoue).\n\n=== Page 22 Image 70 (OCR) ===\na\n\n=== Page 23 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nOverview of top accounts across Commercial and Medicare: current view\n10\nNet sales1\n$M\nMarket \nsegment\nCommer-\ncial\n11%\n7%\n6%\n2%\n2%\n1%\n1%\n1%\n1%\n1%\n11%\n5%\n2%\n1%\n1%\n0%\n54%\n21%\n17%\n13%\n21%\n23%\n20%\n4%\n9%\n3%\n5%\n26%\n14%\n14%\n15%\n17%\n14%\n42%\n35%\n38%\n21%\n28%\n29%\n0%\n20%\n0%\n0%\n56%\n66%\n38%\n40%\n37%\n28%\n112\n992\n193\n21\n102\n26\n21\n7\n12\n11\n6\n258\n155\n26\n20\n8\n5\n10\n73\n17\n18\n113\n63\n15\n9\n6\n6\n113\n13\n17\n53\n5\n4\n545\n2019 contracting\nMedicare \nPart D\nCurrent status (FYE June 2018)\n1 Only account for discretionary rebates to payors, but not other GtN reductions; 2  Includes Admin fee and price protection when applicable; \n3 Assuming status carries over from 201807 period for those accounts with OxyContin formulary access, status based on majority of lives; 4 Prime Therapeutics - excl HCSC: include BCBS NC, MN, KS Horizon BCBSNJ and other \nprime accounts \nAccount\nExpress Scripts\nCaremark\nOptumRx  - United Healthcare\nAetna Health Plans\nPrime Therapeutics - excl HCSC4\nPrime Therapeutics - HCSC\nCigna Healthcare\nProcare\nBCBS FL (Prime Therapeutics)\nIndependence BCBS (PA)\nCaremark\nOptumRx  - United Healthcare\nExpress Scripts\nPrime Therapeutics\nEnvisionRx Options\nTotal\nGross sales\n$M \nMarket \nShare\n% \nNet sales \nOxyContin\n2T Preferred\nNOF\nNOF\n2T Preferred\nNOF\n3T Preferred\n3T Pref PDP/MAPD NOF\nPref MAPD/PDP NOF\n2T Preferred\n2T Preferred\n2T Preferred \n2T Preferred\n2T Preferred\n2T Preferred\nNOF\nMedImpact\n2T Preferred\nRebate2\nXtampza ER3\nNon-preferred\nPreferred\nPreferred\nNon-preferred\nPreferred\nNOF\nPreferred\nNOF\nNOF\nNOF\nNon-preferred\nNon-preferred\nPreferred\nNon-preferred\nPreferred\nPreferred\n2019 formulary status\nCollegium is \nlikely to \ndouble \ndown on big \nnational \naccounts in \norder to \nachieve \nbreak-even\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 23 Image 1 (OCR) ===\n—\n\n=== Page 23 Image 2 (OCR) ===\noe\n\n=== Page 23 Image 3 (OCR) ===\na\n\n=== Page 23 Image 4 (OCR) ===\nQunoue).\n\n=== Page 23 Image 6 (OCR) ===\nguaoue)\n\n=== Page 23 Image 7 (OCR) ===\na\n\n=== Page 23 Image 8 (OCR) ===\nuaoue).\n\n=== Page 23 Image 9 (OCR) ===\neuaoue).\n\n=== Page 23 Image 10 (OCR) ===\na\n\n=== Page 23 Image 11 (OCR) ===\n—\n\n=== Page 23 Image 12 (OCR) ===\noe\n\n=== Page 23 Image 13 (OCR) ===\na\n\n=== Page 23 Image 14 (OCR) ===\nQunoue).\n\n=== Page 23 Image 16 (OCR) ===\nguaoue)\n\n=== Page 23 Image 17 (OCR) ===\na\n\n=== Page 23 Image 18 (OCR) ===\nuaoue).\n\n=== Page 23 Image 19 (OCR) ===\neuaoue).\n\n=== Page 23 Image 20 (OCR) ===\na\n\n=== Page 23 Image 21 (OCR) ===\n—\n\n=== Page 23 Image 22 (OCR) ===\noe\n\n=== Page 23 Image 23 (OCR) ===\na\n\n=== Page 23 Image 24 (OCR) ===\nQunoue).\n\n=== Page 23 Image 26 (OCR) ===\nguaoue)\n\n=== Page 23 Image 27 (OCR) ===\na\n\n=== Page 23 Image 28 (OCR) ===\nuaoue).\n\n=== Page 23 Image 29 (OCR) ===\neuaoue).\n\n=== Page 23 Image 30 (OCR) ===\na\n\n=== Page 23 Image 31 (OCR) ===\n—\n\n=== Page 23 Image 32 (OCR) ===\noe\n\n=== Page 23 Image 33 (OCR) ===\na\n\n=== Page 23 Image 34 (OCR) ===\nQunoue).\n\n=== Page 23 Image 36 (OCR) ===\nguaoue)\n\n=== Page 23 Image 37 (OCR) ===\na\n\n=== Page 23 Image 38 (OCR) ===\nuaoue).\n\n=== Page 23 Image 39 (OCR) ===\neuaoue).\n\n=== Page 23 Image 40 (OCR) ===\na\n\n=== Page 23 Image 41 (OCR) ===\n—\n\n=== Page 23 Image 42 (OCR) ===\noe\n\n=== Page 23 Image 43 (OCR) ===\na\n\n=== Page 23 Image 44 (OCR) ===\nQunoue).\n\n=== Page 23 Image 46 (OCR) ===\nguaoue)\n\n=== Page 23 Image 47 (OCR) ===\na\n\n=== Page 23 Image 48 (OCR) ===\nuaoue).\n\n=== Page 23 Image 49 (OCR) ===\neuaoue).\n\n=== Page 23 Image 50 (OCR) ===\na\n\n=== Page 23 Image 51 (OCR) ===\n—\n\n=== Page 23 Image 52 (OCR) ===\noe\n\n=== Page 23 Image 53 (OCR) ===\na\n\n=== Page 23 Image 54 (OCR) ===\nQunoue).\n\n=== Page 23 Image 56 (OCR) ===\nguaoue)\n\n=== Page 23 Image 57 (OCR) ===\na\n\n=== Page 23 Image 58 (OCR) ===\nuaoue).\n\n=== Page 23 Image 59 (OCR) ===\neuaoue).\n\n=== Page 23 Image 60 (OCR) ===\na\n\n=== Page 23 Image 61 (OCR) ===\n—\n\n=== Page 23 Image 62 (OCR) ===\noe\n\n=== Page 23 Image 63 (OCR) ===\na\n\n=== Page 23 Image 64 (OCR) ===\nQunoue).\n\n=== Page 23 Image 66 (OCR) ===\nguaoue)\n\n=== Page 23 Image 67 (OCR) ===\na\n\n=== Page 23 Image 68 (OCR) ===\nuaoue).\n\n=== Page 23 Image 69 (OCR) ===\neuaoue).\n\n=== Page 23 Image 70 (OCR) ===\na\n\n=== Page 24 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nCurrent access status: OxyContin is preferred for 47% of lives on Prime’s Part D formularies\n11\nSOURCE: MMIT\n• OxyContin is the preferred oxycodone with access to nearly half of Prime lives while Xtampza ER is excluded\n• Zohydro ER is the preferred branded hydrocodone product (Hysingla ER is completely excluded), and Nucynta also maintains access \nto half of Prime lives\n531\n94\n8\n26\n575\n25552\nPrivileged: This presentation contains draft proposals for discussion by Management and are subject to appropriate Purdue legal \nand regulatory review before they can be considered final. These materials are confidential and proprietary.\n1 Includes ~10K lives where no PA/ST required for OxyContin and Nucynta\n2 Defined as percentage of lives that are either preferred or covered (including PA/ST)\nLives, K\nOverall formulary \nstatus\nLives, \n%\nHysingl\na ER\nXtampz\na ER\nOxyCo\nntin\nNucynt\na ER\nZohydr\no ER\n1,235\nOverall covered \nlives %2\n0%\n0%\n47%\n47%\n92%\nLargest formulary\n47\n%\nCollegium \nexcluded1 \nNot \nCovered\nNot \nCovered\nPreferre\nd \n(PA/ST)\nPreferred \n(PA/ST)\nCovered \n(PA/ST)\nBCBS FL BlueMedicare Classic \nand Choice \n43%\nOnly Zohydro - \ncovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nCovered \n(PA/ST) \nHISC Blue Medicare Rx (PDP) \nPlus and Value \n8%\nNo branded ERO \ncoverage\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nRegence BCBS of Oregon \nMedAdvantage + RxClassic PPO \n+ RxEnhanced PPO \n2%\nOnly Zohydro - \npreferred\nNot \nCovered\nNot \nCovered\nNot \nCovered\nNot \nCovered\nPreferred \n(PA/ST)\nBlue Cross Community MMAI \n1\n%\nOxyContin and \nZohydro \npreferred\nNot \nCovered\nNot \nCovered\nPreferre\nd \n(PA/ST)\nNot \nCovered\nPreferred \n(PA/ST)\nBlue Cross Blue Shield of \nMinnesota SecureBlue \nCoverage status of leading ERO brands, \nNov 2018\nPRIME\nTotal\nOxycontin Covered\nNot covered\n11\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 24 Image 1 (OCR) ===\n—\n\n=== Page 24 Image 2 (OCR) ===\noe\n\n=== Page 24 Image 3 (OCR) ===\na\n\n=== Page 24 Image 4 (OCR) ===\nQunoue).\n\n=== Page 24 Image 6 (OCR) ===\nguaoue)\n\n=== Page 24 Image 7 (OCR) ===\na\n\n=== Page 24 Image 8 (OCR) ===\nuaoue).\n\n=== Page 24 Image 9 (OCR) ===\neuaoue).\n\n=== Page 24 Image 10 (OCR) ===\na\n\n=== Page 24 Image 11 (OCR) ===\n—\n\n=== Page 24 Image 12 (OCR) ===\noe\n\n=== Page 24 Image 13 (OCR) ===\na\n\n=== Page 24 Image 14 (OCR) ===\nQunoue).\n\n=== Page 24 Image 16 (OCR) ===\nguaoue)\n\n=== Page 24 Image 17 (OCR) ===\na\n\n=== Page 24 Image 18 (OCR) ===\nuaoue).\n\n=== Page 24 Image 19 (OCR) ===\neuaoue).\n\n=== Page 24 Image 20 (OCR) ===\na\n\n=== Page 24 Image 21 (OCR) ===\n—\n\n=== Page 24 Image 22 (OCR) ===\noe\n\n=== Page 24 Image 23 (OCR) ===\na\n\n=== Page 24 Image 24 (OCR) ===\nQunoue).\n\n=== Page 24 Image 26 (OCR) ===\nguaoue)\n\n=== Page 24 Image 27 (OCR) ===\na\n\n=== Page 24 Image 28 (OCR) ===\nuaoue).\n\n=== Page 24 Image 29 (OCR) ===\neuaoue).\n\n=== Page 24 Image 30 (OCR) ===\na\n\n=== Page 24 Image 31 (OCR) ===\n—\n\n=== Page 24 Image 32 (OCR) ===\noe\n\n=== Page 24 Image 33 (OCR) ===\na\n\n=== Page 24 Image 34 (OCR) ===\nQunoue).\n\n=== Page 24 Image 36 (OCR) ===\nguaoue)\n\n=== Page 24 Image 37 (OCR) ===\na\n\n=== Page 24 Image 38 (OCR) ===\nuaoue).\n\n=== Page 24 Image 39 (OCR) ===\neuaoue).\n\n=== Page 24 Image 40 (OCR) ===\na\n\n=== Page 24 Image 41 (OCR) ===\n—\n\n=== Page 24 Image 42 (OCR) ===\noe\n\n=== Page 24 Image 43 (OCR) ===\na\n\n=== Page 24 Image 44 (OCR) ===\nQunoue).\n\n=== Page 24 Image 46 (OCR) ===\nguaoue)\n\n=== Page 24 Image 47 (OCR) ===\na\n\n=== Page 24 Image 48 (OCR) ===\nuaoue).\n\n=== Page 24 Image 49 (OCR) ===\neuaoue).\n\n=== Page 24 Image 50 (OCR) ===\na\n\n=== Page 24 Image 51 (OCR) ===\n—\n\n=== Page 24 Image 52 (OCR) ===\noe\n\n=== Page 24 Image 53 (OCR) ===\na\n\n=== Page 24 Image 54 (OCR) ===\nQunoue).\n\n=== Page 24 Image 56 (OCR) ===\nguaoue)\n\n=== Page 24 Image 57 (OCR) ===\na\n\n=== Page 24 Image 58 (OCR) ===\nuaoue).\n\n=== Page 24 Image 59 (OCR) ===\neuaoue).\n\n=== Page 24 Image 60 (OCR) ===\na\n\n=== Page 24 Image 61 (OCR) ===\n—\n\n=== Page 24 Image 62 (OCR) ===\noe\n\n=== Page 24 Image 63 (OCR) ===\na\n\n=== Page 24 Image 64 (OCR) ===\nQunoue).\n\n=== Page 24 Image 66 (OCR) ===\nguaoue)\n\n=== Page 24 Image 67 (OCR) ===\na\n\n=== Page 24 Image 68 (OCR) ===\nuaoue).\n\n=== Page 24 Image 69 (OCR) ===\neuaoue).\n\n=== Page 24 Image 70 (OCR) ===\na\n\n=== Page 25 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe defined potential 2020 access scenarios for Oxycontin vs. Xtampza\n2020 Share shift assumptions under different scenarios, 2020 Q4 \n2020 access \nscenarios\nContinue current \naccess status as \nexclusive preferred \noxycodone ER\n1\n1\n1\n2\n3\n15\n7\n14\n4\n4\n10\n4\n4\n10\n6\n5\n5\n6\n7\n5\n8\n4\nOxycontin\nOther \nXtampza\nShare by products (exit share) \nShare shift vs. \nstatus quo \nXtampza covered \n(non-preferred), \nwhile OxyContin \nstays preferred\n2\nLow\nHig\nh\n5%\n35%\nXtampza replaces \nOxycontin as \nexclusive preferred \nwith \ngrandfathering\n3\nLow\nHig\nh\n35%\n55%\nOxycontin Excluded \nwithout \ngrandfathering\n4\nLow\nHig\nh\n50%\n70%\n0%\nENVISION\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 25 Image 1 (OCR) ===\n—\n\n=== Page 25 Image 2 (OCR) ===\noe\n\n=== Page 25 Image 3 (OCR) ===\na\n\n=== Page 25 Image 4 (OCR) ===\nQunoue).\n\n=== Page 25 Image 6 (OCR) ===\nguaoue)\n\n=== Page 25 Image 7 (OCR) ===\na\n\n=== Page 25 Image 8 (OCR) ===\nuaoue).\n\n=== Page 25 Image 9 (OCR) ===\neuaoue).\n\n=== Page 25 Image 10 (OCR) ===\na\n\n=== Page 25 Image 11 (OCR) ===\n—\n\n=== Page 25 Image 12 (OCR) ===\noe\n\n=== Page 25 Image 13 (OCR) ===\na\n\n=== Page 25 Image 14 (OCR) ===\nQunoue).\n\n=== Page 25 Image 16 (OCR) ===\nguaoue)\n\n=== Page 25 Image 17 (OCR) ===\na\n\n=== Page 25 Image 18 (OCR) ===\nuaoue).\n\n=== Page 25 Image 19 (OCR) ===\neuaoue).\n\n=== Page 25 Image 20 (OCR) ===\na\n\n=== Page 25 Image 21 (OCR) ===\n—\n\n=== Page 25 Image 22 (OCR) ===\noe\n\n=== Page 25 Image 23 (OCR) ===\na\n\n=== Page 25 Image 24 (OCR) ===\nQunoue).\n\n=== Page 25 Image 26 (OCR) ===\nguaoue)\n\n=== Page 25 Image 27 (OCR) ===\na\n\n=== Page 25 Image 28 (OCR) ===\nuaoue).\n\n=== Page 25 Image 29 (OCR) ===\neuaoue).\n\n=== Page 25 Image 30 (OCR) ===\na\n\n=== Page 25 Image 31 (OCR) ===\n—\n\n=== Page 25 Image 32 (OCR) ===\noe\n\n=== Page 25 Image 33 (OCR) ===\na\n\n=== Page 25 Image 34 (OCR) ===\nQunoue).\n\n=== Page 25 Image 36 (OCR) ===\nguaoue)\n\n=== Page 25 Image 37 (OCR) ===\na\n\n=== Page 25 Image 38 (OCR) ===\nuaoue).\n\n=== Page 25 Image 39 (OCR) ===\neuaoue).\n\n=== Page 25 Image 40 (OCR) ===\na\n\n=== Page 25 Image 41 (OCR) ===\n—\n\n=== Page 25 Image 42 (OCR) ===\noe\n\n=== Page 25 Image 43 (OCR) ===\na\n\n=== Page 25 Image 44 (OCR) ===\nQunoue).\n\n=== Page 25 Image 46 (OCR) ===\nguaoue)\n\n=== Page 25 Image 47 (OCR) ===\na\n\n=== Page 25 Image 48 (OCR) ===\nuaoue).\n\n=== Page 25 Image 49 (OCR) ===\neuaoue).\n\n=== Page 25 Image 50 (OCR) ===\na\n\n=== Page 25 Image 51 (OCR) ===\n—\n\n=== Page 25 Image 52 (OCR) ===\noe\n\n=== Page 25 Image 53 (OCR) ===\na\n\n=== Page 25 Image 54 (OCR) ===\nQunoue).\n\n=== Page 25 Image 56 (OCR) ===\nguaoue)\n\n=== Page 25 Image 57 (OCR) ===\na\n\n=== Page 25 Image 58 (OCR) ===\nuaoue).\n\n=== Page 25 Image 59 (OCR) ===\neuaoue).\n\n=== Page 25 Image 60 (OCR) ===\na\n\n=== Page 25 Image 61 (OCR) ===\n—\n\n=== Page 25 Image 62 (OCR) ===\noe\n\n=== Page 25 Image 63 (OCR) ===\na\n\n=== Page 25 Image 64 (OCR) ===\nQunoue).\n\n=== Page 25 Image 66 (OCR) ===\nguaoue)\n\n=== Page 25 Image 67 (OCR) ===\na\n\n=== Page 25 Image 68 (OCR) ===\nuaoue).\n\n=== Page 25 Image 69 (OCR) ===\neuaoue).\n\n=== Page 25 Image 70 (OCR) ===\na\n\n=== Page 26 ===\nPROPRIETARY AND \nCONFIDENTIAL\nPROPRIETARY AND \nCONFIDENTIAL\nWe modeled out the economics for Xtampza, Payor and Oxycontin in different access scenarios\n1 Minimum rebate rate required for plan sponsor to favor contracting with Oxycontin vs. exclusive deal with Xtampza, based on plan sponsor net cost analysis; “low share shift”\n2  Maximum rebate rate that Oxycontin could pay so that net sales is higher or equal to the net sales in the “walk-away” scenario where Oxycontin is excluded without grandfathering \n5.9\n6.8\n6.8\n6.2\n4.9\n5.8\n4.8\n4.4\nAccess \nscenarios tested\nXtampza \ncovered (non-\npreferred), \nwhile \nOxyContin \nstays \npreferred\nContinue \ncurrent \naccess status \nas exclusive \npreferred \noxycodone ER\nXtampza \nreplaces \nOxycontin as \nexclusive \npreferred with \ngrandfatherin\ngOxycontin \nExcluded \nwithout \ngrandfatherin\ng\nXtampza net \nsales ($M)\n1\n2\n3\n0%\n50%\n70%\n70%\nAssumed \nXtampza \nrebate\nImplication on Oxycontin bidding strategy\n to maintain current access status assuming no increase, or reasonable increase in rebate rate – payor would be better off maintaining current access vs. \n0.5\n0.2\n0.7\n0.4\n0.5\n0.7\nShare by \nproduct\nOther brand \nnet sales \n($M)\n4\n5\n3\n4\n1\n14\n4\n4\n10\n4\n10\n5\n6\n7\n7\n5\n6\n8\n4\n18\n18\n18\n18\n18\n17\n2.1\n1.4\n1.9\n1.9\n2.2\n2.4\nOxycontin\nXtampza\nOther brands\nSha\nre \nshif\nt\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nLow\nHig\nh\nENVISION\n15\n2\n1 18\n0.7\n0.8\n46%\nBreak-\neven \nrebate2 \n31%\n35%\nN/A\n13%\n33%\nNet sales at min \nrebate ($M)\nRebate rate to keep \nEnvision whole1 \n32%\n22%\n29%\nN/A\n8%\n10%\n24%\nTheoretic\nal – \nunlikely \nable to \nlower \ncurrent \nrate \n(40%)\n16%\n13\nSource:  https://www.industrydocuments.ucsf.edu/docs/ffgg0257\n\n=== Page 26 Image 1 (OCR) ===\n—\n\n=== Page 26 Image 2 (OCR) ===\noe\n\n=== Page 26 Image 3 (OCR) ===\na\n\n=== Page 26 Image 4 (OCR) ===\nQunoue).\n\n=== Page 26 Image 6 (OCR) ===\nguaoue)\n\n=== Page 26 Image 7 (OCR) ===\na\n\n=== Page 26 Image 8 (OCR) ===\nuaoue).\n\n=== Page 26 Image 9 (OCR) ===\neuaoue).\n\n=== Page 26 Image 10 (OCR) ===\na\n\n=== Page 26 Image 11 (OCR) ===\n—\n\n=== Page 26 Image 12 (OCR) ===\noe\n\n=== Page 26 Image 13 (OCR) ===\na\n\n=== Page 26 Image 14 (OCR) ===\nQunoue).\n\n=== Page 26 Image 16 (OCR) ===\nguaoue)\n\n=== Page 26 Image 17 (OCR) ===\na\n\n=== Page 26 Image 18 (OCR) ===\nuaoue).\n\n=== Page 26 Image 19 (OCR) ===\neuaoue).\n\n=== Page 26 Image 20 (OCR) ===\na\n\n=== Page 26 Image 21 (OCR) ===\n—\n\n=== Page 26 Image 22 (OCR) ===\noe\n\n=== Page 26 Image 23 (OCR) ===\na\n\n=== Page 26 Image 24 (OCR) ===\nQunoue).\n\n=== Page 26 Image 26 (OCR) ===\nguaoue)\n\n=== Page 26 Image 27 (OCR) ===\na\n\n=== Page 26 Image 28 (OCR) ===\nuaoue).\n\n=== Page 26 Image 29 (OCR) ===\neuaoue).\n\n=== Page 26 Image 30 (OCR) ===\na\n\n=== Page 26 Image 31 (OCR) ===\n—\n\n=== Page 26 Image 32 (OCR) ===\noe\n\n=== Page 26 Image 33 (OCR) ===\na\n\n=== Page 26 Image 34 (OCR) ===\nQunoue).\n\n=== Page 26 Image 36 (OCR) ===\nguaoue)\n\n=== Page 26 Image 37 (OCR) ===\na\n\n=== Page 26 Image 38 (OCR) ===\nuaoue).\n\n=== Page 26 Image 39 (OCR) ===\neuaoue).\n\n=== Page 26 Image 40 (OCR) ===\na\n\n=== Page 26 Image 41 (OCR) ===\n—\n\n=== Page 26 Image 42 (OCR) ===\noe\n\n=== Page 26 Image 43 (OCR) ===\na\n\n=== Page 26 Image 44 (OCR) ===\nQunoue).\n\n=== Page 26 Image 46 (OCR) ===\nguaoue)\n\n=== Page 26 Image 47 (OCR) ===\na\n\n=== Page 26 Image 48 (OCR) ===\nuaoue).\n\n=== Page 26 Image 49 (OCR) ===\neuaoue).\n\n=== Page 26 Image 50 (OCR) ===\na\n\n=== Page 26 Image 51 (OCR) ===\n—\n\n=== Page 26 Image 52 (OCR) ===\noe\n\n=== Page 26 Image 53 (OCR) ===\na\n\n=== Page 26 Image 54 (OCR) ===\nQunoue).\n\n=== Page 26 Image 56 (OCR) ===\nguaoue)\n\n=== Page 26 Image 57 (OCR) ===\na\n\n=== Page 26 Image 58 (OCR) ===\nuaoue).\n\n=== Page 26 Image 59 (OCR) ===\neuaoue).\n\n=== Page 26 Image 60 (OCR) ===\na\n\n=== Page 26 Image 61 (OCR) ===\n—\n\n=== Page 26 Image 62 (OCR) ===\noe\n\n=== Page 26 Image 63 (OCR) ===\na\n\n=== Page 26 Image 64 (OCR) ===\nQunoue).\n\n=== Page 26 Image 66 (OCR) ===\nguaoue)\n\n=== Page 26 Image 67 (OCR) ===\na\n\n=== Page 26 Image 68 (OCR) ===\nuaoue).\n\n=== Page 26 Image 69 (OCR) ===\neuaoue).\n\n=== Page 26 Image 70 (OCR) ===\na",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 92925,
    "errors": [],
    "success": true
  },
  "metadata_file": {
    "file_name": "ffgg0257-info.pdf",
    "file_path": "Presentations/ffgg0257.zip/ffgg0257-info.pdf",
    "extracted_text": "=== Page 1 ===\nnull - ffgg0257 - Downloaded 31/03/2025 11:11:22 AM\nDocument Information\nTitle: 20181127 Purdue market access strategy update_v1123.pptx\nURL: https://www.industrydocuments.ucsf.edu/docs/ffgg0257\nAuthor: Xiaodong Zhang\nDocument Date: 2018 November 24; 2019 October 27\nType: Presentation\nGenre: Microsoft PowerPoint 2016\nPages: 26\nID: ffgg0257\nCollection: McKinsey Documents\nDrug: Hydrocodone; Hydrocodone Bitartrate; Oxycodone; Tapentadol\nAvailability: public; no restrictions\nBates Number: MCK-MAAG-4862665\nDate Added UCSF: 2022 June 06\nCite This Document\nAuthor. Title. Date. Year. Collection. Source. https://www.industrydocuments.ucsf.edu/docs/[ID]\nXiaodong Zhang. 20181127 Purdue market access strategy update_v1123.pptx. 2018 \nNovember 24; 2019 October 27. McKinsey Documents. Unknown. https://www.\nindustrydocuments.ucsf.edu/docs/ffgg0257\nArtifacts\n1.\t ffgg0257.zip [ 1101.65 kb]",
    "extraction_method": "pymupdf+enhanced_ocr",
    "text_length": 900,
    "errors": [],
    "success": true
  },
  "processed_at": "2025-06-12T12:03:53.888052"
}